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“Life is not easy for any of us. But what of that? We must have perseverance 
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Bacterial infections continue to prove difficult to treat due to the increase of drug 
resistance, but also in the case of intracellular pathogens, poorly permeable anti-
infectives are usually not effective. Encapsulation of anti-infectives into 
nanoparticulate delivery systems, such as liposomes, has been shown to result 
in an enhancement of intracellular delivery. The aim of this study was to formulate 
liposomes for oral delivery of a poorly permeable anti-infective, colistin, and 
functionalize them with a bacterial invasion moiety to enhance their intracellular 
delivery. Different combinations of phospholipids and cholesterol were employed 
to produce colistin-loaded liposomes. Long alkyl chain-containing liposomes 
showed improved stability in terms of colloidal parameters as well as colistin 
retention when compared to the other formulations tested in gastrointestinal 
biorelevant media. The stable formulation was than functionalized with 
extracellular adherence protein (Eap), a Staphylococcus aureus-derived invasion 
protein. Eap-functionalized liposomes loaded with colistin were able to invade 
HEp-2 and Caco-2 monolayers with high efficiency. Treatment of HEp-2 and 
Caco-2 monolayers infected with the enteroinvasive bacteria Salmonella 
enterica, with colistin containing Eap-functionalized liposomes showed a 
significant reduction in the infection load when compared to control i.e. non-
functionalized liposomes. This indicates that such bio-invasive nanocarriers were 
able to promote successful cellular uptake of colistin and mediate anti-infective 
effect intracellularly. Eap-functionalized liposomal nanocarriers offer a promising 







Bakterielle Infektionen erweisen sich aufgrund der zunehmenden 
Arzneimittelresistenzen weiterhin als schwierig zu behandeln. Zudem sind bei 
intrazellulären Bakterien schlecht  permeabele Antiinfektiva normalerweise nicht 
wirksam. Es wurde gezeigt, dass die Einkapselung von Antiinfektiva in 
nanopartikuläre Trägersysteme, wie beispielsweise Liposomen, zu einer 
Verbesserung des Transports in Zellen führt. Diese Studie zielte darauf ab, 
Liposomen für die orale Applikation des schlecht permeablen Antibiotikums 
Colistins zu formulieren und diese mit einem bakteriellen Invasionsmolekül zu 
funktionalisieren, um ihre intrazelluläre Verfügbarkeit zu verbessern. 
Unterschiedliche Kombinationen von Phospholipiden und Cholesterin wurden 
verwendet, um mit Colistin beladene Liposomen herzustellen Lange Alkylketten 
enthaltende Liposomen zeigten im Vergleich zu den anderen in simulierten 
Magen-Darm-Medien getesteten Formulierungen eine verbesserte Stabilität 
sowohl hinsichtlich ihrer kolloidalen Stabilität als auch der Colistinretention. Diese 
stabile Formulierung wurde dann mit extrazellulärem Adhäsionsprotein 
(„extracellular adherence protein” Eap), einem von Staphylococcus aureus 
gewonnenen Invasionsprotein, funktionalisiert. Mit Colistin beladene Eap-
funktionalisierte Liposomen konnten mit hoher Effizienz in dichte Zellschichten 
von HEp-2- und Caco-2-Zellen eindringen. Die Behandlung von HEp-2- und 
Caco-2-Monoschichten, die mit dem enteroinvasiven Bakterium Salmonella 
enterica infiziert wurden, mit Colistin-beladenen; Eap-funktionalisierten 
Liposomen führten zu einer signifikanten Verringerung der Infektionslast im 
Vergleich zur Behandlung mit nicht funktionalisierten Liposomen. Dies ist ein 
Beleg dafür, dass solche bio-invasiven Nanocarrier die erfolgreiche zelluläre 
Aufnahme von Colistin fördern und somit die intrazelluläre antiinfektiöse Wirkung 
ermöglichen können. Somit bieten die entwickelten Eap-funktionalisierten 
Liposomen eine vielversprechende Strategie zur Verbesserung der Therapie 
intrazellulärer Infektionen des Magen-Darm-Trakts. 
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1.1  Intracellular infections 
Bacterial infections are among the most frequent life-threatening diseases 
worldwide, with over 10 million deaths registered every year (Kraker et al. 2016; 
PLOS Medicine Editors. 2016). These pathogens can be found either 
extracellularly living as free microorganisms in their habitats, or creating complex 
forms by invading their surrounding niches and causing intracellular infections 
(McClure et al. 2017). Nowadays, intracellular infections still represent a major 
threat to human and animal populations, as they have proven themselves to be 
targets which are hard to reach. These species of pathogens can be internalized 
by host cells following passive or active pathways. In the passive mode of 
invasion, pathogens are internalized by phagocytosis which is a common route 
used by professional phagocytic host cells such as macrophages, dendritic cells 
and neutrophils. During this process, the bacteria do not require an energy-
dependent activity such as mycobacteria (Pieters 2008) and legionellae 
(Weissgerber et al. 2003). However, other bacterial species are able to invade 
non-phagocytic cells, upon attachment to certain receptors or via virulence factor-
mediated mechanisms. The zipper strategy used by Yersinia and Listeria spp. 
involves the ligation of pathogenic agents to specific receptors on the host cell 
membrane such as integrins or cadherins. These interactions stimulate 
cytoskeletal pseudopod-like structures, leading to the engulfment of pathogens 
(Ham et al. 2011; Ribet and Cossart 2015) (Figure 1.1 a, b). On the other hand, 
salmonellae and shigella possess a type III secretion system, which can 
penetrate the host cell membrane and secrete virulence factors called the trigger 
mechanism to induce cytoskeletal rearrangements. This results in engulfment of 
the bacteria via membrane protrusions named ruffles (Cossart and Roy 2010; 
Pizarro-Cerdá and Cossart 2006) (Figure 1.1 c, d). After their internalization, 
these pathogenic agents are capable of replicating inside intracellular 
compartments called vacuoles (a strategy used by bacteria such as Salmonella 
and Mycobacterium), or escaping into the cytosol where further replication occurs 
(as occurs for example with Listeria and Shigella) (Ham et al. 2011). 






Figure 1.1. Mechanisms of bacterial entry into host cells 
Invasion routes of Yersinia (a), Listeria (b) using the zipper strategy characterized 
by receptor-mediated internalization through the binding of invasin (Yersinia) to 
Integrin receptors and Internalin A (InIA, Listeria) to E-cadherin receptors. 
Salmonella (c) and Shigella (d) applying the trigger strategy via their type III 
secretion system mediating the secretion of different proteins (SipA, SipC, SopE, 
SptP and SopB in Salmonella infection) and (IpgD, IpaC, VirA and IpaA in shigella 
infection) which regulate actin cytoskeleton dynamics. Figure adapted from 
(Cossart and Sansonetti 2004). 
Such invasive strategies, among others, allow these bacteria to escape immune 



































macrophages, organisms which cannot survive intracellularly are mainly digested 
within a maximum of 30 min during fusion of the phagosome with lysosome. 
Digestion is ensured by the content of phagosomes, including nitric oxide and 
oxygen species, as well as antimicrobial peptides present for example in some 
epithelial cells and neutrophils (Hassett and Cohen 1989; Nicolas and Mor 1995). 
However, intracellular bacteria possess, and are capable of developing if needed, 
a variety of strategies to overcome phagosome-lysosome digestion. Yersinia spp. 
have the ability to prevent phagocytosis by interacting with phagocyte receptors 
and blocking the process (Fällman et al. 2001). Shigella and Listeria spp. secrete 
toxins, which are able to lyse phagosomes and therefore facilitate bacterial 
escape into the cytosol (Paz et al. 2010; Pizarro-Cerdá et al. 2016). In contrast, 
Legionella spp. interfere with phagosome and lysosome fusion, while 
Mycobacterium spp. impede acidification of the phagolysosome which generally 
occurs as a result of phagosome and lysosome fusion (Pizarro-Cerdá et al. 2016; 
Levitte et al. 2016). Salmonella spp. employ yet another different mechanism, 
which involves alteration of phagocytosis mechanism and resistance to the 
antimicrobial activity into the phagolysosome (Pizarro-Cerdá et al. 1997). Besides 
evading the action of the immune system, these pathogenic agents may also be 
capable of resisting the action of anti-infectives such as beta-lactams, or 
presenting a hard target to access for other antibiotics to access – this may be a 
result of poor intracellular retention, as is the case for macrolides and 
fluoroquinolones, or due to low antibiotic permeability, as is exhibited by 
aminoglycosides (Salouti and Ahangari 2014). 
Regardless of the type of entry mechanism these pathogens employ, once able 
to reside and replicate within host cells, they can induce complicated and life-
threatening diseases such as pneumonia as well as foodborne illnesses. 
Salmonella is one of the global causes of foodborne illnesses. 550 million people 
are affected each year by this diarrheal disease, including over 220 million 
children, as stated by the World Health Organization in February 2018. 
Salmonella, the rod-shaped motile Gram-negative bacteria from the 
Enterobacteriaceae family, is divided in two species: S. bongori, and S. enterica 
(Su and Chiu 2007). S. enterica has six subspecies, which include more than 
2600 serotypes (Gal-Mor et al. 2014). From a clinical perspective, Salmonella is 




divided into two categories: typhoidal (invasive) or non-typhoidal (non-invasive) 
Salmonella (Okoro et al. 2012). Non-typhoidal serotypes can infect either animals 
or humans, and the disease can be transferred from animal to human. As 
intracellular pathogens, they can invade the cellular barrier of the gastrointestinal 
(GI) tract causing salmonellosis, where the symptoms are usually self-limiting 
such as fever, abdominal pain, diarrheas, and sometimes vomiting. However, 
these invasive serotypes can cause more serious complications such as 
paratyphoid fever, which requires anti-infective therapy in most cases. On the 
other hand, typhoidal serotypes are restricted to human hosts, and are 
characterized by their ability to invade the GI tract barrier and make their way 
through the lymphatic system to the bloodstream (causing typhoid fever). 
Moreover, they can disseminate further into different organs and release toxins 
causing septic shock, which usually requires anti-infective treatment and 
intensive care (Ryan et al. 2004). Regarding the treatment, this is generally not 
required in healthy individuals with mild or moderate symptoms. However, some 
exceptions occur in the case of children and the elderly; treatment may also prove 
necessary in immunocompromised individuals. Ampicillin, chloramphenicol and 
sulfamethoxazole-trimethoprim, which were previously the first line of treatment 
in this case, are no longer an appropriate choice due to the increase in bacterial 
resistance to these anti-infectives; fluoroquinolones and third generation 
cephalosporins are therefore now taking the lead in the treatment scheme. The 
lower susceptibility of Salmonella towards these anti-infective classes has 
however led to considerable concern regarding treatment of such pathogens. In 
addition, the Food and Drug Administration (FDA) reported in July 2018 warnings 
concerning fluoroquinolone prescriptions, stating that the use of these anti-
infectives might lead to hypoglycemia and neural system dysfunction. Therefore, 
there is a major need for new drugs or new therapeutic strategies for the 
treatment of such intracellular pathogenic agents. 
  




1.2 Anti-infectives: past and present 
In 1947, Selman Waksman first introduced the world to the word “Antibiotic”, a 
term defined as a small molecule derived from pathogenic agents, capable of 
either inhibiting the growth of a micro-organism or eliminating it altogether (Clardy 
et al. 2009). An antibiotic interferes with bacterial survival via a specific 
mechanism of action, which also requires a specific therapeutic concentration. 
This specific therapeutic concentration should be sufficient to achieve high 
efficacy regarding inhibition or elimination of the pathogenic agent while causing 
minimal toxicity (Ren et al. 2015). 
 
 
Figure 1.2. Anti-infective mechanisms of action 
Illustration showing classification of antibiotics and their mechanisms of action. 
Different bacterial sites including the cell wall and membrane, DNA, RNA and 
protein synthesis are targeted by different antibiotic molecules. Figure adapted 
from (Bbosa et al. 2014). 
Beta lactams including penicillins, cephalosporins, carbapenems and 
monobactams act on the bacterial cell wall, leading to the inhibition of synthesis 
of peptidoglycan and causing lysis of bacterial cells (Peterson and Kaur 2018). 
Following their penetration into the bacterial cell, other antibiotics are able to 





















































aminoglycosides interfere with mRNA translation by interacting with rRNA of the 
30S subunit, while chloramphenicol, oxazolidinones and macrolides interact with 
the 50S ribosomal subunit (Vannuffel and Cocito 1996; Wise 1999). Quinolones 
on the other hand are able to inhibit DNA replication by interacting with the 
bacterial enzyme DNA gyrase (Higgins et al. 2003), while rifampicin acts on the 
RNA polymerase; sulfonamides as well as trimethoprim interfere with folic acid 
metabolism by inhibiting distinct steps involved in its synthesis (Yoneyama and 
Katsumata 2006) (Figure 1.2). However, due to the ability of several bacterial 
pathogens to acquire sophisticated survival strategies to overcome antibiotic 
activity, the spread of anti-microbial resistance (AMR) is accelerating leaving 
humanity with major challenges (Coates et al. 2011; Aslam et al. 2018).  
Since discovery of the first antibiotic Penicillin by Alexander Fleming in 1928, and 
the beginning of its use for treatment of infections in 1942, more than 20 classes 
of antibiotics have been discovered and marketed – this occurred in the period 
between 1940 and 1960, which is considered as the Antibiotic Golden Age 
(Powers 2004; Coates et al. 2002). In fact in 1970, Surgeon General William 
Stewart stated that it was time ‟to close the book on infectious diseases„ and 
focus more on hard-to-treat diseases such as cancer" (WHO 2018). Since that 
period only two antibiotic classes have been discovered and some analogues of 
existing classes have reached the market (Infectious Diseases Society of 
America 2010; Venter et al. 2017; Dahal and Chaudhary 2018) (Figure 1.3).  
Currently, approximately 20% of worldwide deaths are related to infectious 
diseases, despite a 36% increase in antibiotic usage (Martens and Demain 2017; 
Laxminarayan et al. 2016). Therefore, in 2017 the World Health Organization 
(WHO) released a global priority list of anti-microbial resistant bacteria in order to 
help scientists prioritize their research to develop alternative treatments. This list 
includes multiple drug resistance (MDR) Pseudomonas aeruginosa, 
Enterobacteriaceae, Salmonella and Shigella (WHO Report 2017).  





Figure 1.3. A history of anti-infective discovery and corresponding 
evolution of bacterial-resistance 
Timeline illustrating the history of antibiotics discovery since 1940 in comparison 
to the appearance of different bacterial resistance over time. Figure adapted from 
(amr-bioMérieux 2019). 
The Polymyxin class of anti-infectives, and in particular colistin, a polypeptide 
anti-infective discovered in the late 1950s, initially fell out of favor but are now 
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infections. After the discovery of colistin and its immediate use in the clinic, 
several toxicity cases were reported (Koch-Weser 1970). However, due to the 
lack of alternative treatments for such infections at that time, colistin was 
considered as the only choice despite the lack of a proper understanding of its 
pharmacokinetics and pharmacodynamics properties. Shortly after the 
emergence of aminoglycosides (which exhibited a lower toxicity compared to 
colistin) in the early 1980s, the use of polymyxins was gradually phased out (Li 
et al. 2006).  
Colistin, with a molecular weight of 1750 Da, consists of a cationic heptapeptide 
ring linked to a tripeptide side chain, conferring hydrophilic properties on the 
molecule. In addition, the side chain is coupled through an α-amide linkage to a 
fatty acid chain, functioning as a hydrophobic tail (Falagas and Kasiakou 2005). 
Colistin is furthermore a multicomponent anti-infective, composed mainly of 
Colistin A and B which differ in the length of their fatty acid tails (6-methyloctanoic 
acid in colistin A and 6-methylheptanoic acid in colistin B) (Li et al. 2005). As a 
bactericidal agent, it interacts with lipopolysaccharide (LPS) molecules mainly 
Lipid A of the Gram-negative bacterial membrane through electrostatic 
interactions (Figure 1.4). This interaction leads to a displacement of the cations 
Mg+2 and Ca+2 which disturbs the outer membrane, leading to a leakage of the 
cell contents and subsequently cell death (Biswas et al. 2012). Commercially, 
colistin is available as colistin sulfate and colistin methanesulfonate (CMS). The 
latter is a prodrug of colistin and the more commonly used form, due to its lower 
toxicity compared to colistin sulfate. It is used for parenteral administration or as 
a nebulized formulation for pulmonary infections (Gurjar 2015; Landersdorfer et 
al. 2017; Yapa et al. 2013). Colistin sulfate is only administered topically for skin 
infections, or in very limited way orally for bowel decontamination, due to its low 
bioavailability (Yahav et al. 2012; Falagas and Kasiakou 2005). Several studies 
have been performed in recent years to understand and optimize the dosage of 
colistin and investigate in a detailed manner its pharmacokinetics and 
pharmacodynamics properties in healthy as well as in ill patients (Karaiskos et al. 
2015; Rao et al. 2014). The dosage of CMS intravenously recommended by the 
FDA is 2.5 to 5 mg CBA/kg (colistin base activity), corresponding to 31250 to 
62500 International Unit (IU)/kg per day divided into 2 to 4 equal doses, for an 




individual with normal creatinine clearance (≥80 mL/min). In contrast, the 
European Medicines Agency (EMA) approved dose per day is 9 million IU 
(approximately 300 mg CBA) (Nation et al. 2016). However, approximately 30% 
of CMS is converted to colistin while most of it is eliminated in urine – this  makes 
treatment using CMS less efficient in terms of colistin dose after conversion, but 
less harmful compared to colistin in terms of toxicity (Jacobs et al. 2016).  
To improve the use of colistin for infection therapy via a range of administration 
routes, several strategies have been explored, such as using nanoparticulate 
delivery systems. These systems have shown to play a major role in improving 
the efficacy of different drugs by increasing their concentration at the site of action 
and extending their half-life to achieve an optimal effect at the site of action. The 
improvement of drug efficacy is also due to the enhanced permeation using 
nanocarriers especially for hydrophilic drugs such as colistin (Mohammed et al. 
2016; Salama and Aburahma 2016). 





Figure 1.4. Colistin structure and mechanism of action 
(a) Chemical structure of colistin, which consists of D-Leucine, L-threonine and L-
α-γ-diaminobutyric acid. (b) Colistin mechanism of action indicating the 
interaction of positively charged colistin amino acids with Lipid A of LPS which 
displaces cations leading to disruption of the membrane and cell death. Figure 





























Colistin A  R = (+) 6-methyloctanoic acid
Colistin B  R = 6-methylheptanoic acid




1.3 Oral delivery  
Oral administration of drugs remains the most preferred route due to its simplicity 
and high patient compliance, as it offers a high degree of convenience in terms 
of self-medication, flexibility especially for chronic conditions. This route is also of 
interest for economic reasons as it does not require sterile conditions and 
complex production procedures, both of which can inflate manufacturing costs. 
Oral administration is also of interest due to physiological reasons. The 
gastrointestinal (GI) tract has an extensive surface area of 180-300 m2, allowing 
for a large drug absorption capability through diverse cell types (Ensign et al. 
2012; Hunter et al. 2012). The GI tract contains epithelial cells, namely 
enterocytes, which are largely responsible for the absorption of nutrients and/or 
drugs. Other cells may be involved in the absorption process as well such as 
goblet cells, Paneth cells and Microfold (M) cells associated with Peyer’s patches, 
which transport antigens through dendritic cells (DCs) (Pawar et al. 2014; Pridgen 
et al. 2015). However, various hydrophilic and hydrophobic drugs such as 
aminoglycosides and polyene anti-infectives exhibit a poor bioavailability 
following oral administration as a result of physicochemical and/or 
biopharmaceutical limitations including solubility, stability and/or permeability 
problems (Leo et al. 2010; Thornton and Wasan 2009; Hamman et al. 2005).  
Several studies have proven that the use of nanocarriers can alter the stability, 
permeability and solubility of many drugs and therefore improve their 
bioavailability following oral delivery (Ross et al. 2004; Smart et al. 2014). 
However, the preclinical development of such nanoparticulate systems requires 
specific design considerations for each region of the GI tract to ensure better drug 
absorption and less side effects (Pandey and Khuller 2007; Liu et al. 2018; Gao 
et al. 2013). 
 Gastrointestinal tract environment 
The complexity of the GI tract is characterized by the presence of enzymes and 
varying environmental pH, as well as numerous chemical and physical barriers. 
This represents a significant challenge for the successfully delivery not only of 
drugs and biologics, but also for sophisticated nanomedicines – in particular lipid-




based nanoparticulate systems, such as liposomes (liposomes will be described 
further in Section 1.4) (Garg et al. 2014; Lipp 2013). Following oral administration, 
nanocarriers encounter various conditions in the GI tract. As a first obstacle, the 
pH within the stomach ranges from 1 to 3 and can increase to 5 in the presence 
of food. From the pyloric region of the stomach to the ileum in the small intestine, 
the pH shifts to a basic environment ranging from 5.7 to 7.7. However, pH values 
decrease in the cecum again to a value of approximately 6, before increasing 
gradually to a value of 7 within the colon. This acidic environment and variations 
of pH throughout the GI tract disrupt the majority of nanoparticulate structures 
and lead to their instability and leakage of their payload. In addition to pH 
considerations, a variety of enzymes and molecules are present at each level (He 
et al. 2019). Gastric fluids contains lipases and proteases, while at the small 
intestine level, the duodenum contains bile salts and various enzymes including 
trypsin, amylase and lipase. Furthermore, the small intestine is rich in a variety of 
pancreatic enzymes, namely pancreatin, peptidases, lipases and maltase. This 
extremely acidic and enzymatically harsh habitat can affect the stability of lipid-
based nanocarriers such as liposomes as well as their payload before they even 
reach the cellular level of the GI tract. Majority of liposomal formulations following 
their incubation for 2 h with biorelevant media, show colloidal deformation such 
as irregular shapes and damaged lipid bilayers. Moreover, presence of bile salts 
and lipases induce hydrolysis of liposomal phospholipids in particular lipids with 
lower transition temperature that lead to disruption of liposomes structure (Liu et 
al. 2015; Tian et al. 2016; He et al. 2019). At the cellular level, the mucus layer 
lining the surface of the GI tract plays a major role in determination of the 
absorption of orally administrated drugs. The epithelial cells underlying this 
mucus layer are additionally connected by tight junctions which acts as an 
effective barrier against absorption of macromolecules and fluids, allowing these 
calls to act as the gatekeepers of the GI tract (Figure 1.5) (Choonara et al. 2014; 
Nguyen et al. 2016; Raza et al. 2019). 
 





Figure 1.5. Gastrointestinal tract challenges for oral delivery 
(a) Schematic representation illustrating gastrointestinal environment including 
pH and different compositions of fluid in the stomach, small and large intestine. 
(b) Zoom in view of the small intestine illustrating chemical and physical barriers 
including mucus layer and different cell types such as enterocytes, M cells bound 
to Peyer’s patches and the underlying immune cells. Figure adapted from 
(Truong-Le et al. 2015). 
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Despite these challenges, considerable efforts have been and are still currently 
focused on improving the ability of various nanocarriers (including liposomes) to 
withstand these harsh environmental conditions and counter the highly protective 
cellular barriers. The stability of these carriers in order to provide continues cargo 
protection is of particular concern, as an ultimate means to overcome the 
intestinal biological barrier and deliver the incorporated drug to its site of action. 
1.4  Liposomes as a delivery system 
Over 50 years ago, the British biophysicist Alec Bangham described liposomes 
for the first time (Bangham et al. 1965). The discovery was a results of his 
observation that phospholipids dispersed in water form vesicles which are 
structurally and functionally similar to cell membranes, enclosing two 
compartments; lipid bilayer and an aqueous cavity (Figure 1.6) (Düzgüneş and 
Gregoriadis 2005). Since then, liposomes have progressed from being a 
biophysical phenomenon to a successful delivery system, and widely used for 
several applications (Jesorka and Orwar 2008; Bulbake et al. 2017).  
 
Figure 1.6. Liposomal structure 
Illustration of unilamellar liposome, characterized by a spherical-shaped lipid 
bilayer made from phospholipids and cholesterol, in which hydrophobic drugs are 
incorporated. Lipid bilayer enclose an aqueous compartment in which hydrophilic 
drugs can be encapsulated. Figure adapted from (Talegaonkar et al. 2006). 
Since 1995 in particular, tremendous progress in liposomal technology has 












Doxil® (100 nm stealth liposomes encapsulating doxorubicin hydrochloride) 
(Barenholz 2012), and AmBisome® (Amphotericin B encapsulated in liposomes 
of 70 nm size) (Adler-Moore and Proffitt 2002). Despite the appearance of several 
pharmaceutical carriers over the years, the interest in liposomes remains high – 
approximately 5000 articles concerned with various applications of liposomes 
have been published in the last 5 years, equating to approximately 3 articles per 
day (statistics from Springer Link). While various applications have been 
investigated, liposomes have mostly been employed to date as a delivery system 
for pharmaceuticals (Karmali and Chaudhuri 2007; Sercombe et al. 2015), as 
components of a membrane model (Mouritsen 2011), or as chemical micro-
reactors (Lemière et al. 2015). Such studies have led to major breakthroughs, 
which have driven the rapid development of liposomes as pharmaceutical 
therapeutics over the last 15 years. New preparation methods and formulation 
approaches have further been developed in order to enhance their usage (Samad 
et al. 2007), including introduction of various amphiphilic components into the 
liposomal bilayer to increase their blood circulation half-life (e.g. using stealth 
moieties). Interaction of conventional liposomes following their administration into 
the circulation with proteins has traditionally resulted in poor liposomal stability 
and high clearance rate. By modulating the physical characteristics of liposomes 
such as their size and charge, coating of liposomes with a neutral water soluble 
polymer e.g. polyethylene glycol (PEG) confers the ability to extend their 
circulation time and evade opsonization (Pasut et al. 2015; van Slooten et al. 
2001; Nag and Awasthi 2013). Another strategy employed to develop liposomes 
with better penetrating capabilities for topical applications, is the addition of 
single-chain surfactants. These molecules act as membrane modifiers causing 
destabilization of liposomal lipid bilayer, resulting in an increased liposome 
deformability and an increased capacity to squeeze between skin compartments 
(Elsayed et al. 2006; Hussain et al. 2016; Karande and Mitragotri 2009). 
Interestingly, although extensive studies of liposome applications have been 
carried out, few studies have shown that liposomes can be employed for the oral 
delivery of anti-infectives (and especially hydrophilic anti-infective molecules). 
The instability of these lipid-based nanoparticulate systems once exposed to 
different aspects of the gastrointestinal (GI) environment presents a major 




challenge that often ultimately to low absorption of the encapsulated drug. (Wu 
et al. 2015).  
1.4.1 Liposome modulation to improve stability 
Modification of liposomal compositions and/or surface properties has emerged as 
a trend to change the fate of liposomes following their oral administration and 
overcome the aforementioned GI-related challenges (Figure 1.7).  
 Lipid composition 
Conventional liposomes consist of phospholipids and most commonly 
cholesterol, with similarities to cellular membranes. The phase transition 
temperature of lipids – defined as the temperature required to induce a physical 
state change from fully extended and well packed hydrocarbons chains, known 
as the crystalline gel state, to a disordered fluidic state known as the liquid 
crystalline state (Jacobson and Papahadjopoulos 1975) – plays a major role in 
liposome stability. This parameter is influenced by various factors including fatty 
acid chain length and degree of saturation, as well as head group type and/or 
charge. Incorporation of long alkyl chain phospholipids into liposomal 
compositions reinforces van der Waals interactions, leading to a greater energy 
requirement for disruption of the liposomal closely packed bilayer and therefore, 
increases the phase transition temperature (Tm) above 37 °C. On the other hand, 
presence of unsaturated bond in the alkyl chain induces a stearic hindrance that 
increases distances between the molecules and prohibits the closed packaging 
of the lipid bilayer. This lead to reduced chain-to-chain interactions and therefore 
rendering the liposomal membrane less stable (Ali et al. 2013; Briuglia et al. 
2015). Additionally, incorporation of cholesterol at a specific molar ratio 
percentage (~ 30%) into the bilayer leads to a condensing action. This has been 
shown to improve liposomal integrity by mediating phospholipid hydrophobic 
chain alignment, enabling an orderly behavior of lipid alkyl chains (Parmentier et 
al. 2012; Briuglia et al. 2015; Róg and Pasenkiewicz-Gierula 2001). 
Liposomes containing specific lipids or cholesterol analogues are also capable of 
serving as an adaptable system for the delivery of poorly permeable or unstable 
drugs (Muramatsu et al. 1996). Parmentier and his colleagues showed that 




liposomes containing dipalmitoyl phosphatidylcholine (DPPC) and tetraether 
lipids derived from Sulfolobus acidocaldarius improved the bioavailability of the 
encapsulated octapeptide octreotide after oral administration in rats by 
approximately 4 fold using different types of tetraether lipid derivatives 
(Parmentier et al. 2011). Another study revealed that substitution of cholesterol 
with plant-derived sterols such as ergosterol resulted in the formation of 
liposomes capable of protecting insulin against GI tract degradation, and induced 
a significant hypoglycemic effect in rats (Cui et al. 2015). Several bile salts such 
as sodium taurocholate and sodium deoxycholate have also been incorporated 
into liposomes for the delivery of antigens (Shukla et al. 2008; Aburahma 2016), 
poorly soluble small drug molecules (Aburahma 2016; Guan et al. 2011) and 
macromolecules (Niu et al. 2012; Niu et al. 2011) . Although the underlying 
mechanism by which bile salt incorporation into liposomes improves oral drug 
bioavailability has not been completely clarified, offsetting the degrading potential 
of endogenous bile salts present in GI tract could be the main drive for this 
enhancement (He et al. 2019).  
 Surface coating 
As another approach to overcome the harsh conditions of the GI tract, coating of 
liposomal surfaces with various polymers has emerged. In early development 
stages, enteric polymers such as the Eudragits were utilized to protect liposomes 
in the acidic environment of stomach (Hosny et al. 2013). However, these 
Eudragit-coated liposomes could not sustain the destructive effect of bile salts 
(Barea et al. 2010; Barea et al. 2012). Various polysaccharides have also been 
employed as coating materials for liposomes, including O-palmitoylpullutan 
(Carafa et al. 2006; Lee et al. 2005), pectin (Smistad et al. 2012; Willats et al. 
2006) and chitosan (Alshraim et al. 2019; Nguyen et al. 2014; Venkatesan and 
Vyas 2000). Among these various coating materials, charged polymers have 
shown greater achievements in terms of liposomes protection as well as 
interaction with cell membranes. Chitosan as a cationic polymer ensures an 
optimal coating of negatively charged liposomes and therefore, is able to provide 
an optimal shield against GI tract acidity and enzymes. Additional to the 
aforementioned coating materials, polyelectrolytes have emerged as innovative 




nanocarriers in drug delivery – in particular, oral delivery of proteins (Dwivedi et 
al. 2010; Mohanraj et al. 2010) and some drugs (Jain and Kumar et al. 2012; Jain 
and Patil et al. 2012; Li et al. 2012). As an example of this strategy, a layer by 
layer approach was used in order to coat doxorubicin-loaded liposomes, 
consisting of a deposition of the anionic poly(acrylic acid) followed by the cationic 
polyallyl amine hydrochloride. This led to the formation of stable coated vesicles 
termed ‘layersomes’ (Jain and Kumar et al. 2012; Jain and Patil et al. 2012).  
 Interior thickening 
The colloidal stability of liposomes may also be modulated by increasing the size 
of the interior aqueous compartment. This alteration can be achieved by 
modification of the interior compartment viscosity, or by incorporation of hydrogel 
beads (Kazakov 2016; Miguel et al. 1995). Liposomes containing charged and 
cross-linked polysaccharides within their central cores have also been found to 
be stable carriers for proteins (Hoegen 2001; Miguel et al. 1995). Another study 
showed that incorporation of polymerized PEG–dimethacrylate to lthe aqueous 
core of liposomes consisting of soybean PC and cholesterol led to an 
improvement of their structural properties (Petralito et al. 2014). 
 Other approaches 
Filtration of prepared liposomes through glass filters coated with lipid bilayers, as 
performed by Ebato and his colleagues, was shown to result in a considerable 
increase in the ability of encapsulated salmon calcitonin to decrease calcium 
levels in blood, as compared to calcitonin incorporated within conventional 
liposomes (Ebato et al. 2003). An improvement of the hypoglycemic effect was 
also achieved using similar strategy by Katayama and his colleagues (Katayama 
et al. 2003). In another study, egg phosphatidylcholine/cholesterol (PC/CHOL) 
liposomes were stabilized by adding gelatin as a thickening platform in which 
liposomes were embedded (Pantze et al. 2014). This system was employed as 
an optimal dosage form for the controlled release of highly water soluble 
macromolecules. 




1.4.2 Liposome modulation to improve permeability 
 Mucoadhesives 
Coating of liposomes with mucoadhesive-acting materials such as cationic 
polymers has shown to result in an increase in the absorption of either liposome-
associated payloads, or the payload alone. The positive polymeric charge 
increases the possibility of liposome interaction with the negatively charged 
mucus layer of the small intestine, therefore slowing liposome clearance. 
Liposomes coated with various chitosan derivatives have been reported to show 
a more prolonged efficacy compared to un-coated vesicles (Manconi et al. 2010; 
Sugihara et al. 2012). However, the molecular weight of chitosan has a great 
impact on the degree of mucoadhesion and thereby influences the in vivo efficacy 
of the delivery system (Thongborisute et al. 2006). Coating of liposomes with 
PEG showed also an extended penetrating effect in the GI tract due to the ability 
of PEG to penetrate deeply into mucosal barrier, leading to an enhanced uptake 
of liposomes (Minato et al. 2003).  
 Bio-enhancers 
Incorporation of oral bio-enhancers such as cetylpyridinium chloride, 
stearylamine and cholylsarcosine into liposomes has also been found as an 
effective strategy to orally deliver hydrophilic molecules. Beside their role in 
increasing the oral absorption, without exhibiting any typical drug activity, these 
bio-enhancers are able to inhibit degradation in the GI tract by affecting e. g. the 
efflux pumps and some metabolic enzymes (Kesarwani and Gupta 2013). 
Parmentier and his colleagues investigated the impact of various bio-enhancers 
with different properties on the oral absorption of fluorescein isothiocyanate-
dextran, by assessing their permeation capacity and cytotoxicity (Parmentier et 
al. 2010). The study was conducted in vitro using Caco-2 monolayers as a GI 
tract model, with results showing that each of the investigated bio-enhancers 
(when used at a specific percentage) enhanced permeation of the payload. A 
potential shortcoming of this study however is that non-cellular aspects of the GI 
tract, namely the intestinal fluids and the mucus layer, were not represented. 
Liposomes containing surfactants such as sodium glycocholate have been found 




to have a greater GI stability, as mentioned above; inclusion of sodium 
glycocholate within liposomes has also proven to significantly enhance their 
permeation through the intestinal barrier (Guan et al. 2011). Non-ionic surfactants 
such as Tween 80 have further been incorporated into liposomes containing PC 
and cholesterol to form elastic vesicles encapsulating catechin. The produced 
liposomes showed an optimal stability in simulated intestinal fluids and greater 
accumulation of the drug at the target site compared to the control (Huang et al. 
2011). 
 Muco-penetrators 
As an example of muco-penetrating systems, thiomer-coated liposomes were 
formulated by Gradauer and her group, using the modified chitosan derivative 
chitosan–thioglycolic acid further conjugated with 6, 6′-dithionicotinamide, 
resulting in a chitosan–thioglycolic acid 6-mercaptonicotinamide-conjugate. 
Owing to the ability to resist degradation, these liposomes exhibited a potential 
to form disulfide bonds with the mucus layer and thereby enhanced the 
permeation of salmon calcitonin across the mucosal barrier in rats (Gradauer et 
al. 2013). Pluronic F127, a synthetic tri-block copolymer of poly(ethylene oxide)-
poly(propylene oxide)-poly (ethylene oxide), was found to improve intestinal 
mucus penetration of various payloads encapsulated within liposomes and 
mediate their cellular uptake after oral administration (Li, X. et al. 2011; Zhu et al. 
2013).  





Figure 1.7. Strategies for the oral delivery of liposomes 
Scheme illustrating different strategies to enhance liposomal stability in order to 
withstand challenges associated with the GI tract environment. These strategies 
include modifying the lipid composition, coating of the liposomal surface or 
increasing the innermost bilayer leaflet of the liposomes (left panel). The right 
panel demonstrates possibilities to enable and/or improve the trafficking of 
liposomes through the mucosal barrier including the use of mucoadhesive 
agents, incorporation of bio-enhancers or insertion of specific targeting moieties 
such as antibodies, sugars or proteins. Figure adapted from (He et al. 2019). 
 Invasive moieties for active targeting 
The progress in nanotechnology research in recent years has resulted in different 
strategies to further optimize nanoparticulate delivery systems such as liposomes 
to overcome their lack of specificity and insufficient delivery of the payload. 
Several parameters may play a role and have an effect on their behavior once 
applied either in in vitro simple cellular setups, or within complicated ex/in vivo 
systems. Size, shape and surface charge, as well as nanocarrier composition can 
determine their delivery pathway and affect their function, with the impact of 
modulating composition on stability and permeability having been discussed 
above. Functionalization of nanocarrier surfaces has further emerged as an 



















additional design step, aimed at the fabrication of more sophisticated 
nanocarriers able to be directed to particular target sites and manipulated with 
respect to their cell interactions and uptake. Diverse ligands and moieties 
including vitamins, synthetic and natural compounds as well as peptides have 
been used to achieve active targeting of delivery systems towards cancer cells, 
increase their circulation life, or improve their internalization into various 
eukaryotic cells. Since most lipids and proteins within the mucosal lining of the 
intestine are glycosylated, lectins, a family of proteins able to bind mono- and 
oligo-saccharides with high affinity, emerged as possible targeting moieties in 
1988. Although lectins were identified much earlier, in1860, when Stillmark 
described in his thesis the agglutination phenomenon of ricin (Bies et al. 2004), it 
was not until more than 100 years later that Woodley described lectins as 
promising moieties for GI tract targeting (Naisbett and Woodley 1994). Lehr and 
colleagues later demonstrated that tomato lectin-functionalized polystyrene 
microspheres were able to bind to enterocytes, however the presence of mucin 
was seen to reduce this interaction (Lehr et al. 1992). Since that time, discovery 
of various lectins from plant or animal origins as well as their usage has increased 
dramatically. Wheat germ agglutinin (WGA) was coupled to poly(lactide-co-
glycolide) nanoparticles for delivery of anti-tuberculosis drugs in guinea pigs. 
Results showed a significant improve of rifampicin, isoniazid and pyrazinamide 
absorption, in which three doses were sufficient to eradicate mycobacterial 
colonies versus 45 doses of oral free drug (Sharma et al. 2004). Sashini and his 
co-authors described in their study on oral ulcerative lesions that liposomes with 
conjugated WGA and loaded with a β-lactam antibiotic were able to immediately 
bind to epithelial cells and ensure sustained and localized drug release 
(Wijetunge et al. 2018).  
Since the penetration ability of the transactivator of transcription (Tat) peptide 
was demonstrated, cell-penetrating peptides (CPPs) –  short peptides that 
facilitate cellular intake/uptake of various - have been widely used either 
conjugated to drug molecules as delivery systems (Kristensen et al. 2015; 
Morishita et al. 2007) or functionalized to nanocarrier surfaces as penetrating 
moieties (Torchilin et al. 2003). Penetration of insulin-labeled with fluorescein and 
conjugated to Tat was shown to be significantly enhanced compared to free 




insulin, however the study was only conducted in vitro (Liang and Yang 2005). In 
another study, interferon-β was coupled to either oligoarginine or penetratin as 
cell-penetrating peptides, with an increase in the intestinal absorption noted only 
with penetratin (Kamei et al. 2008). Various studies have suggested an instability 
of these CPPs, due to relative susceptibility to peptidases and proteases in the 
GI tract. This lack of stability plays a major role in their limited usage to date for 
oral delivery (Khafagy and Morishita 2012). 
An interesting, related approach has been employed recently, which is based on 
imitating natural strategies employed by some pathogenic agents to cross 
biological barriers in our bodies and establish a niche in order to replicate, 
disseminate and cause serious complications. Such pathogens use an arsenal of 
virulence factors which are expressed on their cell surface for a direct interaction 
with host cells, or are secreted either into the host cellular compartments. As a 
prominent example, internalins of Listeria (InIA, InIB) are located on the bacterial 
surface and mediate bacterial adhesion and internalization into various cell types. 
It has been shown that InIA interacts with E-cadherin receptors on epithelial cells 
and promotes the invasion of Listeria through the intestinal cell barrier of the GI 
tract. On the other hand, the combinations “InIB - HGF” (hepatocyte growth 
factor) and “InIB – gC1q-R” (complement receptor) lead to the internalization of 
Listeria into endothelial cells as well as hepatocytes. Neisseria spp. exhibit 
extracellular virulence proteins Opa and Opc that promote their binding to several 
receptors including CEACAMs (carcinoembryonic antigen-related cell adhesion 
molecules), as well as the integrins α7β3 and α5β1 via interaction with extracellular 
matrix membrane (ECM) proteins, which moderate its uptake by a variety of host 
cells. Moreover, Yersinia spp. exhibit several invasion proteins, with invasin 
(InvA) being one of the most well characterized. InvA promotes the internalization 
of Yersinia spp. into M cells of the intestinal barrier via interaction with β1 integrin 
receptors. It has been shown that the last 197 amino acids C-terminal fragment 
of InvA is able to function as an efficient ligand during the invasion of Yersinia 
into epithelial cells (Dersch and Isberg 1999). Keeping in mind - the efficiency of 
the above mentioned pathogens to invade easily our cellular barriers- it could be 
beneficial to functionalize nanocarrier surfaces with these proteins, thereby 
simulating the mechanism of bacterial entry via their own invasive tools to achieve 




maybe the same efficiency with our nanoparticulate delivery systems. Previous 
studies adopting this strategy have shown the promising aspect of using these 
bacterial invasive proteins to enhance the uptake of non-invasive pathogens 
(Haggar et al. 2003) as well as nanocarriers (Labouta et al. 2015; Menina et al. 
2016). Liposomes functionalized with InvA497, a transmembrane protein of 
Yersinia species that plays a major role in the binding and entry of the pathogen 
into mammalian cells through interaction with β1 integrin receptors, were used to 
facilitate the intracellular delivery of the poorly permeable anti-infective 
gentamicin. Treatment of HEp-2 cells infected with either Yersinia 
pseudotuberculosis or S. enterica showed that this formulation was able to 
reduce the infection load of both pathogens, indicating that such a strategy holds 
a great promise for the delivery of anti-infectives intracellularly (Lehr et al. 2016). 
1.5 Extracellular adherence protein (Eap) 
In the early 90s, different groups of scientists were able to independently identify 
and isolate from the wide Staphylococcus aureus repertoire of secreted 
molecules a protein named Eap. This protein has been found to play a major role 
in the pathogenicity of S. aureus not only by promoting adhesion to targeted 
surfaces but also by interfering with the host defense system (McGavin et al. 
1993; Vogt et al. 1983; Harraghy et al. 2003). The structure was found to exhibit 
a modular architecture consisting of 4 to 6 tandem repeats of ~ 97 residue EAP 
domain. Depending on the bacterial strain, the molecular mass of Eap is around 
50 – 70 kDa, and comprises four to six repeats linked with 9 – 12 residue regions 
of unknown structure. The biochemical characteristics of these domains have 
further not been well studied, which presents a major hurdle in understanding the 
full functionality of Eap (Hammel et al. 2007). Early investigations of Eap showed 
that this protein is able to bind to a wide array of plasma and ECM proteins, 
including fibrinogen, fibronectin and vitronectin as well as to pro-inflammatory cell 
surface receptors such as intrercellular Adhesion Molecules 1 (ICAM-1) 
(Chavakis et al. 2002). Eap has also shown the capability to re-bind to S. aureus 
surfaces following secretion; this effect was investigated and proved by Hussain 
and colleagues by adding free Eap to Staphylococcus cultures or adding various 
types of pathogens to immobilized Eap (Hussain et al. 2002). The mechanism of 




Eap binding  to host/mammalian cell surfaces is still unclear, however Palma et 
al., suggested that Eap binding is due to non-specific interactions Eap-surface 
interactions, and a receptor-mediated process is unlikely (Palma et al. 1999). 
Adherence of Eap to eukaryotic cells has also been investigated using an eap 
mutant strain of S. aureus Newman. The study demonstrated a significant 
decrease of the internalized number of bacteria into fibroblasts and epithelial cells 
in comparison to the wild type. However, the internalization capacity was restored 
to some extent after addition of external Eap. Moreover, the addition of anti-Eap 
antibodies led to inhibition of the internalization process. This indicates the ability 
of Eap to bind not only to bacterial surfaces and proteins but also to eukaryotic 
cells, promoting the internalization of pathogens (Haggar et al. 2003). Eap 
adhesive properties demonstrate that this protein could be a promising candidate 
to promote the internalization of nanoparticulate delivery systems into eukaryotic 
cells. Microspheres and beads have previously been coated with Eap for 
functional determination, without therapeutic purpose (Joost et al. 2011); to the 
best of our our knowledge, the current study is the first to investigate the ability 
of Eap to mediate the internalization of nanocarriers for drug delivery. 
  





The aim of the current study is to develop a stable nanocarrier capable of 
improving the cellular internalization of the poorly permeable colistin, as a 
strategy for combating hard-to-treat intracellular infections. Colistin, despite being 
an old anti-infective, it has gained attention due to its high efficacy against MDR 
bacteria. Moreover, the low intrinsic permeability and the possible gain in the 
safety profile which, could be achieved by employing liposomes as a delivery 
system were behind the motivation of using colistin as payload. The oral route is 
interesting not only due to patient compliance but also as a step-down therapy 
following intravenous administration in serious infections. However, from a 
delivery point of view, the oral route is highly challenging for liposomes, in which 
the release of colistin in the intestinal lumen should be minimized and high 
intracellular delivery should be achieved. In order to address the latter point, the 
uptake into non-phagocytic cells of the GI tract, a bio-invasive strategy, mimicking 
one of the bacterial pathways of internalization was utilized. 
The main objectives of this thesis were as following: 
I. Formulation of liposomes loaded with colistin aimed to be achieved by 
formulating first unloaded liposomes with different compositions and subject 
them to colloidal stability studies. Selected formulations will be loaded further 
with different colistin concentrations in order to identify the optimal 
concentration which shows the highest entrapment efficiency. 
II. Challenge of colistin-loaded liposomes stability against various simulated 
media of the GI tract in order to evaluate its capacities to withstand its 
different conditions. 
III. Functionalization of liposomes with an invasive moiety as a strategy to 
improve the intracellular delivery of the nanoparticulate system. Different 
methods of coupling will be investigated. The invasive moiety was kindly 
provided by our collaboration partner Prof. Markus Bischoff from the Institute 
of Medical Microbiology and Hygiene (Institute of Infectious Medicine, 
Saarland University Hospital).  




IV. Assessment of the capacity of the system to facilitate the internalization of 
colistin to the interior of epithelial cells and achieve an intracellular eradication 
of the pathogen. A comparison between Eap and our previously investigated 
invasive moiety InvA497 will be performed to evaluate the efficiency of each 
system to internalize colistin-loaded liposomes. InvA497 was kindly provided 
by Prof. Rolf Müller’s group (Microbial Natural Products group at the 
Helmholtz Institute for Pharmaceutical Research Saarland). 
  





3 Materials and Methods 
3.1 Materials 
Table 1. Material used in this study 
Material Abbr. Properties Provider 
1,2-Dipalmitoyl phosphatidylcholine 
(Lipoid E PC) 
DPPC  - 






ethanolamine-N-(lissamine rhodamine B 
sulfonyl) (ammonium salt) 
Rh-DPPE -  





Cholesterol CHOL ≥ 99%  
 
 




EDC ≥ 99% 
Ammonium thiocyanate NH4SCN ≥ 97.5% 
Newborn calf serum (heat inactivated, 
sterile-filtered) 
NCS  
Trypsin  0.5 g/L 
Chloroform CHCl3 ≥ 99.9% 
Colistin sulfate Col USP 
Grade 
Adipogen AG (Liestal, 
Switzerland) 
Potassium dihydrogen phosphate KH2PO4 -  
Merck KGaA (Darmstadt, 
Germany) 
Ferric 3-chloride-hexahydrate FeCl3.6H2O - 
Sodium hydroxide NaOH - 
Methanol CH3OH ≥ 99.9% VWR Chemicals (Fontenay-sous-
Bois, France) 
Hydroxysuccinimide NHS ≥ 99.0% Carbolution Chemicals (St. 
Ingbert, Germany) 
All other chemicals and solvents used were of an analytical grade. 





3.2 Liposomes preparation  
Lipid film hydration method described previously by Bangham and his colleagues 
was used to prepare liposomes (Bangham et al. 1965). Briefly, DPPC and DSPC 
as main phospholipids were mixed either separately with cholesterol or as a 
combination of the two phospholipids together with cholesterol to form liposomes 
(Table 2). DPPE-GA was added to all formulations in a molar ratio of 0.2 (w/w) 
to facilitate the functionalization of these nanocarriers through their carboxylic 
groups. The mixtures were dissolved in chloroform: methanol (2:1 v/v) in round-
bottomed flask. A 10 µg/ml of Rh-DPPE was added to label the liposomes for the 
imaging experiment (red fluorescence). 
Table 2. Liposomes composition 










Rotary evaporator (BUCHI Laboratory AG, Switzerland) set at 200 mbar, 120 rpm 
and equipped with a heating bath set at either 70° C for DPPC-containing 
liposomes or 75° C for DSPC-containing liposomes, was used to evaporate the 
solvent mixture for 1 h. A following evaporation step (40 mbar for 30 min) was 
used to ensure the complete evaporation of the organic solvent. The dry lipid film 
was hydrated with either phosphate buffer saline (PBS, pH 7.4) solution to 
prepare unloaded liposomes (Lip-1, Lip-2 and Lip-3) or with different 
concentrations of colistin from 1 mg/mL to 10 mg/mL in PBS to obtain colistin-
loaded liposomes (Col-Lip-1, Col-Lip-2 and Col-Lip-3). The hydration step was 
performed by setting the rotation at 75 rpm and the heating bath at 50° C for 
DPPC-containing liposomes or 55° C for DSPC-containing liposomes for 1 h. The 
formed vesicles were then extruded 10 times through 200 nm polycarbonate 
membrane using LiposoFast LF-50 extruder (Avestin, Germany) (Figure 3.1) to 
obtain small unilamellar liposomes (SUV).  





Centrifugal ultrafiltration was used to purify the liposomal suspensions and 
remove the non-encapsulated colistin. Briefly, liposomes were placed into 
Centrisart® tubes (Sartorius AG, Germany) equipped with a membrane of 
300.000 MWCO and centrifuged two cycles at 3270 g and 4° C for 30 min each. 
After each cycle, the filtrate was collected to quantify the non-encapsulated 
colistin and fresh PBS was added to the liposomal suspension instead of the 
filtrate. Liposomes were stored afterwards at 4° C in glass scintillation vials. 
 
Figure 3.1. Liposomes preparation 
Scheme illustrating liposomes preparation steps, (1) starting with a formation of 
dry lipid film by evaporating solvent mixture, which was used to dissolve different 
phospholipids and cholesterol (2) Evaporation step was followed by hydration of 
the dry lipid film with colistin solution for liposomes loaded with colistin or only 
PBS to prepare unloaded liposomes. The formation of multi-lamellar vesicles (3) 
was followed by an extrusion process (4) through 0.2 µm membrane to obtain 
small unilamellar colistin-loaded liposomes. 
3.3 Characterization of liposomes 
3.3.1 Colloidal characterization 
Colloidal parameters of nanocarriers is an important factor which influences their 
stability, uptake and release of the payload at the target site. Therefore, 
liposomes were subjected to size, polydispersity index (PDI) and ζ-Potential 
measurements.  
Hydrodynamic diameter and size distribution of liposomes were measured using 
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Germany). DLS measurement is based on the Brownian motion of the vesicles in 
a fluid, a transfer of energy is induced due to the collision of particles with the 
fluid molecules leading to particles movement. Direction of the laser towards the 
sample, scatters the light due to particles movement and invoke fluctuations in 
intensity signal over time which is used then to determine the size using the 
Stokes-Einstein equation (Stetefeld et al. 2016). Briefly, purified liposomal 
samples were diluted 1:1000 in PBS and then measured at 25° C using a 
refractive index of 1.33 (Dorrington et al. 2018). 
Laser Doppler Micro-electrophoresis technique on the other hand was applied to 
determine the surface charge of liposomes. The principle of this technique is 
based on the induction of an electric field to the liposomal suspension, in which 
the direction and particles velocity is proportional to their electrical voltage and 
therefore their charge. Measurements were conducted after a dilution of 1:1000 
of the liposomal samples with PBS in folded capillary cell using Nano Zetasizer.  
3.3.2 Colistin quantification 
An ultimate 3000 high performance liquid chromatography (HPLC) system from 
Dionex equipped with diode array detector, a column oven, an autosampler and 
a pump (Thermo Scientific, Germany) was used to quantify colistin. Briefly, the 
detection of colistin two main peaks (Colistin A and B) was achieved using a 
method previously described by Bai and his colleagues with some modifications 
(Bai et al. 2011). A mobile phase composed of acetonitrile: 0.1% trifluoroacetic 
acid (TFA) was used to elute colistin through LiChrospher® 100, RP-18 (5 μm), 
125 x4 column (Merck KGaA, Germany) in a gradient mode from 20:80 (v/v) to 
50:50 (v/v) during 10 min. The elution in a flow rate of 1 mL/min was followed by 
5 min washing step with 50:50 (v/v) acetonitrile: 0.1% TFA for 2 min and then 
increased gradually back to 20:80 (v/v). A 100 µL volume was used to analyze 
samples and the column oven was set at 30° C during all the analysis. A stock 
solution of 500 µg/mL of colistin was prepared by dissolving colistin in 0.1% TFA 
solution, then diluted 1:5 with acetonitrile. Standards from 10 µg/mL to 100 µg/mL 
were prepared accordingly, and then analyzed in HPLC vials.  





Colistin standards were prepared each time freshly to validate the method in 
which precision, specificity, linearity, accuracy, detection limit and quantification 
limit were determined. Standards aliquots were also stored at 4°C for intra- and 
inter-day validation analysis.  
Samples were prepared by diluting purified liposomes 3:7 (v/v) in same eluent 
used to prepare standards (0.1% TFA: Acetonitrile 20:80 v/v) and analyzed in 
triplicates. The amount of colistin was determined by plotting the sum of the area 
under the curve (AUC) of both colistin peaks A and B detected at a wavelength 
of 210 nm into the equation. 
3.3.3 Phospholipids quantification 
Phospholipids content was quantified utilizing a colorimetric assay previously 
described by Stewart (Stewart 1980). The assay is based on the measurement 
of the optical density of phospholipids - ammonium ferrothiocyanate complex at 
485 nm. The assay reagent was prepared by dissolving FeCl3 6H2O and NH4SCN 
in water. Standards (5, 10, 20, 30, 40 and 50 µg/mL) were prepared from 0.1 
mg/mL DPPC or DSPC stock solutions in chloroform, each at a final volume of 2 
mL in screw cap round-bottomed glass tubes. A 100 µL of liposomes (1:10 in 
PBS) was mixed with 1.9 mL chloroform and then 2 mL of ferrothiocyanate 
reagent was added to the samples and to the standards. Samples as well as 
standards were vortexed for 20 seconds and then centrifuged at 300 g for 10 
minutes to obtain two phases in which the lower phase containing liposomal lipids 
dissolved in chloroform (total amount). Lipids-chloroform mixture transferred to a 
glass cuvette was subjected to an optical density measurement at 485 nm. The 
amount of phospholipids in liposomes was determined by plotting samples values 
in the corresponding calibration curve equation. 
3.3.4 Cholesterol quantification 
Cholesterol was quantified using the above described HPLC system 
(Section3.3.2), using a method described previously by Simonzadeh 
(Simonzadeh 2009). A mobile phase composed of acetonitrile: methanol (70:30 
v/v) with a flow rate of 2 mL/min was used to elute the samples with an injection 





volume of 100 µL in an isocratic mode. Cholesterol’s peak was detected at a 
wavelength of 210 nm after 15 min analysis time. Standards were prepared from 
a stock solution of 200 µg/mL of cholesterol in 50:50 (v/v) acetonitrile: 
methanol/ethyl acetate (1/1 v/v). Whereas, samples were prepared by mixing 400 
µL of liposomes (1:10 in PBS) with 1 mL of acetonitrile: methanol/ethyl acetate 
mixture. The amount of cholesterol in each sample was determined by comparing 
their absorbance values to that of standards. 
3.3.5 Entrapment efficiency and loading capacity 
The encapsulation efficiency of colistin-loaded liposomes was calculated using 
the Equation 1 (Papadimitriou and Bikiaris 2009) after direct determination of the 
amount of encapsulated colistin using HPLC as described previously in 
Section 3.3.2. 
Equation 1: Entrapment efficiency 
𝐸𝐸 % =  
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓  𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑑𝑟𝑢𝑔
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑢𝑠𝑒𝑑 𝑑𝑟𝑢𝑔
 × 100 
 
After the determination of the amount of all liposomal components including 
phospholipids, cholesterol and colistin, loading capacity was determined using 
Equation 2 (Papadimitriou and Bikiaris 2009) as following: 
Equation 2. Loading capacity 
𝐿𝐶 % =  
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑑𝑟𝑢𝑔
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑎𝑙𝑙 𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑎𝑙 𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡𝑠
 × 100 
 
3.3.6 Thermal characterization  
In order to determine the thermo-physical properties of liposomes mainly the 
transition temperature which could be an indicator of liposomal stability, 
differential scanning calorimetric technique (DSC) was performed (Bunjes and 





Unruh, 2007). DSC is a direct thermo-analytical technique for determination of 
the enthalpy of biomolecules and nano-sized materials. This technique is based 
on the measurement of the thermo-dynamic properties of materials by 
determining the temperature and the heat flow associated with material 
transitions as a function of time and temperature (Demetzos, 2008), (Mabrey and 
Sturtevant, 1976). The basic principle underlying this technique is to compare the 
rate of heat flow to the sample and to an inert material which are heated or cooled 
at the same rate. Changes in samples´ heat absorption induce change in the 
differential heat flow resulting in a peak. The area under the peak is proportional 
to the enthalpy change and its direction indicates the type of the thermal event 
either endothermic or exothermic. 
Briefly, liposomes and gentamicin loaded liposomes were firstly frozen for 4 hours 
at -80°C and then placed on the freeze dryer (CHRIST Lyocube 4-8 LSC Freeze 
Dryer, Germany) to obtain a powdered form. Around 3 to 5 mg of Col-Lip-1, Col-
Lip-2 and Col-Lip-3 were weighted in separated hermetic aluminum sample pans 
(PerkinElmer, USA) and covered with hermetic aluminum Lids (PerkinElmer, 
USA) and closed. Liposomes were subjected to a heating rate of 10°C/min in the 
20 - 80°C using DSC 8000 (PerkinElmer, USA). The data were analyzed using 
Pyris - Instrument Managing Software (Version 11 PerkinElmer, USA)  
3.4 Stability studies in biorelevant media 
Liposomal suspensions were incubated with simulated media (1:10 v/v) in 24-
well plate, three wells for each time point. The plates were incubated at 37° C for 
5 hours at 180 rpm. At each time point, samples were collected and 100 µL was 
used for immediate colloidal properties measurements and the left was placed in 
Centrisart tubes for a purification step to remove the released colistin (as 
described previously in Section 3.2). Afterwards, samples were analyzed with 
HPLC to determine colistin content.  






Figure 3.2. Stability study workflow 
Liposomes were incubated in 24-well plate containing different media separately 
(1) for 5 h at 37° C at least 3 wells for each time point, afterwards Size, PDI and 
ζ-potential of collected samples were measured directly (2). Then samples were 
purified (3) to remove the amount of released colistin and then analyzed using 
HPLC to quantify colistin concentration (4). 
3.4.1 Fasted state simulated gastric fluid (FaSSGF) 
The gastric medium was prepared as described previously (Jantratid et al. 2008). 
Briefly, a lipid film was prepared by evaporating the organic solvent of 160 µL 
phosphatidylcholine (0.125 µM in chloroform) using a gentle nitrogen stream. 
Afterwards, a 43.01 mg of sodium taurocholate dissolved in 100 mL of HCL (0.02 
M) pre-warmed to 37° C was added to hydrate the lipid film and form micelles. 
After mixing, the suspension was kept for stirring at 37° C overnight and protected 
from light. In the meanwhile, in another bottle 100 mg of pepsin and 1.999 g of 
sodium chloride were dissolved in 100 mL of pre-warmed HCL (0.02 M) and 
stirred overnight at 37° C as well. Afterwards, the contents of the two bottles were 
mixed and then 700 mL of pre-warmed HCL (0.02 M) was added. After mixing, 
the pH of the prepared medium was adjusted to 1.6 with HCL (1 M), and the 
volume to 1 L with Milli-Q water. The final concentrations of each component of 















Table 3. Simulated media composition 
a)FaSSGF: fasted state simulated gastric fluid. b)FaSSIF: fasted state simulated 
intestinal fluid. c)FaSSIF-Enz: fasted state simulated intestinal fluid containing 
enzymes (pancreatin). d)FeSSIF: fed state simulated intestinal fluid. e)Pancreatin 
was added only in FeSSIF. 
3.4.2 Fasted state simulated intestinal fluid (FaSSIF) 
The simulated intestinal fluid in fasted state was prepared either without enzymes 
(FaSSIF) (Jantratid et al. 2008) or with enzymes (FaSSIF-Enz) (Sassene et al. 
2014). A blank FaSSIF was prepared first by dissolving 0.348 g of NaOH, 3.438 











Sodium taurocholate (mM) 0.08 3 15 
Phosphatidylcholine (mM) 0.02 0.75 3.75 
Pepsin (mg/mL) 0.1 - - 
Sodium chloride (mM) 34.2 105.9 65.1 
Oleic acid (mM) - - 5 
Monoolein (mM) - - 2.5 
Maleic acid (mM) - - 100 
Sodium azide (mM) - - 3 
Lipase (Pancreatin) 
(USP/mL) 
- 600e) - 
Ad. deionized water (mL) 1000 500 50 
pH 1.6 6.5 6.5 





the buffer was adjusted to 6.5 and the volume to 1 L. Then, 1.65 g of sodium 
taurocholate was dissolved in 250 mL of blank FaSSIF and 5.9 mL of 
phosphatidylcholine (100 mg/mL in dichloromethane) was added. After mixing, 
the organic solvent was evaporated by placing the mixture on the rotary 
evaporator using a vacuum set at 250 mbar for 15 min followed by another 15 
min at 100 mbar (water bath set at 40° C). After cooling, the volume of the mixture 
was adjusted to 1 L with blank FaSSIF. Simulated intestinal fluid-containing 
enzymes was prepared in a similar manner to FaSSIF, with the addition of an 
enzyme mixture to bile salts and phospholipids after the evaporation step. The 
suspension of enzymes was prepared by dissolving 7.48 g of porcine pancreatin 
in 37.4 mL of blank FaSSIF, and then centrifuged at 4° C, 4500 rpm for 7 min. 
The supernatant of the solution containing the enzymes was added then to the 
bile salts and phospholipids mixture to a final concentration of 600 U/mL of lipase 
in the simulated medium (Figure 3.3). 
 
Figure 3.3. Scheme illustrating FaSSIF-enz preparation protocol 
(1) Blank FaSSIF pre-prepared with different salts at pH 6.5 was used to dissolve 
pancreatin. (2) A centrifugation of pancreatin suspension at 4500 rpm and 4° c 
for 7 min was performed in order to extract the enzymes in supernatant and 
sediment all undesired components. (3) The supernatant containing enzymes 
NaTC in BF 




7 min, 4500 rpm at 













mixture was collected. (4) Sodium taurocholate (NaTC) dissolved in blank 
FaSSIF was mixed with phosphatidylcholine (PC) dissolved in dichloromethane 
(DCM). (5) Evaporation of the solvent lead to a formation clear suspension 
containing micelles, and then (6) enzymes mixture was added to NaTC/PC 
suspension to obtain FaSSIF-Enz. 
3.4.3 Fed state simulated intestinal fluid (FeSSIF) 
As described previously by Nielsen and his colleagues (Nielsen et al. 2013), 
FeSSIF was prepared by mixing 3 mL of phosphatidylcholine (125 mM) and 0.625 
mL of oleic acid (800 mM) / mono-olein (400 mM) in blue-capped bottle. The 
organic solvent was evaporated with gentle nitrogen stream in order to form a dry 
lipid film. Afterwards, 20 mL of maleic acid (500 mM)/sodium azide (15 mM) and 
26.04 mL of NaCl containing 0.8066 g of sodium taurocholate was added to 
hydrate the lipid film and form micelles in the suspension. A volume of 20 mL 
Milli-Q water was added and the bottle kept for stirring overnight at 37° C. The 
following day, the pH of the mixture was adjusted to 6.5 and the volume to 100 
mL with Milli-Q water (Figure 3.4). 
 
Figure 3.4. Scheme illustrating FeSSIF preparation protocol  
(1) Phosphatidylcholine (PC) and mixture of oleic acid/monoolein (OA/MO) were 
dissolved in chloroform in separate Erlenmeyer flasks. (2) The dissolved lipid and 
fatty acids were mixed together and a nitrogen stream was used to evaporate the 
organic solvent resulting on lipid film. (3) Sodium chloride (NA) and oleic 
acid/sodium azide (OA/SA) solutions prepared in separate Erlenmeyer flasks 
MA/SA
PC in chloroform






at 37 °C FeSSIF (pH 6.5)
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were added the lipid film for hydration. (4) Sodium taurocholate (NaTC) was 
added to the suspension and stirred overnight at 37° C to obtain FeSSIF with a 
pH of 6.5. 
3.5 Liposomes functionalization 
To enhance the internalization of liposomes into epithelial cells, liposomes were 
functionalized with the invasive moiety Extracellular Adherence Protein (Eap) 
using two different methods. The adhesive nature of Eap allowed for physical 
adsorption (ads) on the liposomal surface and the presence of carboxylic groups 
on liposomes enable the possibility for a covalent coupling (cov). Surface 
adsorption was achieved by incubating 2 mL of liposomes (1:10 in PBS) with 40 
µg/mL of Eap. The suspension was kept for stirring (180 rpm) at room 
temperature for 1 h. Whereas, covalent coupling was performed in two steps 
procedure; activation of liposomal carboxylic groups using either 4-(4, 6-
dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) reagent 
or 1-ethyl -3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) / N-
hydroxysuccinimide (NHS) reagents in order to determine the efficient method to 
achieve high functionalization efficiency (Figure 3.5). Briefly, 2 mL of liposomes 
were mixed with 300 µL of DMTMM (1 mg/mL) and stirred for 2 h at room 
temperature, or 300 µL of EDC/NHS (48 mM and 19 mM respectively) (Menina 
et al. 2016) for 3 h at 4°C. Afterwards, 40 µg/mL of Eap solution was added to 
liposomes and kept for stirring for another hour at room temperature. Liposomal 
suspensions were all purified using Centrisart tubes (as described previously in 
Section 3.23.2) to remove the unbound Eap and excess of reagents. After 
centrifugation, liposomes were subjected to two cycles of sonication of 50% 
amplitude for 30 seconds each with an interval of 2 min using ultrasonic probe 
Sonicator S-250D model (Branson Ultrasonics, USA) to disperse the liposomal 
suspension.  






Figure 3.5. Functionalization methods  
(1) Surface adsorption achieved by adding Eap to liposomal suspension which 
lead to adsorption of Eap onto liposomes (2) A covalent coupling of Eap to 
liposomal surface using DMTMM reagent, which activates the carboxylic groups 
on surface to form an amide bound between Eap amino groups. (3) A covalent 
coupling achieved using EDC reagent, which activates the carboxylic groups on 
liposomal surface, forming an unstable ester intermediate, stabilized by the 
addition of NHS reagent, and lead to a link with Eap amino groups via amide 
bound. 
3.5.1 Determination of Eap concentration  
Due to the interference of colistin; as a polypeptide, with the common protein 
quantification assays such as Bicinchoninic Acid Protein Assay (BCA) and 
Bradford assay, SDS-PAGE as a semi-quantitative method was used on one 
hand to confirm the presence of Eap on liposomal surface, and on the other hand 



















migration of charged protein molecules in an electric field towards the positive 
side. Samples are treated with SDS detergent to denature proteins secondary, 
tertiary and quaternary structures by disturbing non-covalent forces including 
hydrogen-bonding, hydrophobic and ionic interactions. SDS also as anionic 
detergent gives a negative charge to protein molecules (Bhuyan 2010). 
Moreover, a treatment with 2-Mercapthoethanol as a reducing reagent is applied 
to cleave their disulfide bounds. This allows the proteins to be unfolded to linear 
chains and migrated through the gel matrix in a proportional manner to the 
polypeptide chain length (Figure 3.6). 
The gel was based on 12% (w/v) acrylamide with a thickness of 0.75 mm, 
prepared by mixing 3.4 mL of Milli-Q water, 2.5 mL of resolving buffer (1.5 M Tris-
HCL, pH 8.8), 100 µL of 10 % SDS solution and 4 mL of N, N’- 
Methylenebisacrylamide solution (Serva, Germany). Afterwards, 50 µL of 10% 
ammonium persulfate (APS) and 5 µL of N, N, N’, N’-tetramethylenediamine 
(TEMED) (Carl Roth GmbH, Germany) were added to the mixture and stirred 
gently with pipette tip in order to initiate the polymerization. Standards and 
samples were mixed (1:1 v/v) with a reducing agent that cleaves disulfide bonds. 
Afterwards, samples were loaded as well as protein ladder then placed into 
electrophoresis chamber containing electrophoresis buffer composed of 3.03 g 
Tris base, 14.4 g glycine and 1 g SDS (pH 8.3). Electrophoresis was conducted 
at 120 mV for 40 min. Page Blue Protein staining was used to stain the gel after 
a washing step with water for 1 h under a gentle shaking. The gel was then rinsed 
again with water and destained overnight in a water bath at room temperature 
and gentle shaking. Gel DocTM EZ imager (Bio-Rad, Germany) was used to image 
the gel and ImageJ software to process the images.  






Figure 3.6. Scheme illustrating SDS-PAGE principle 
(1) Folded proteins with negative and positive charges. (2) In presence of SDS, 
proteins were charged negatively and denatured by cleavage of non-covalent 
interactions and (3) disulfide bonds in presence of reducing agent to form linear 
negatively-charged structures (4). Separation of proteins based on their 
polypeptide molecular weight on polyacrylamide gel (5). 
3.5.2 Functionalization efficiency 
The amount of Eap was determined using SDS-PAGE and expressed as 
functionalization efficiency calculated using the following equation: 































𝐹𝐸 (%) =  
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑞𝑢𝑎𝑛𝑡𝑖𝑓𝑖𝑒𝑑 𝐸𝑎𝑝
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐸𝑎𝑝
 × 100 
3.5.3 Stability of Eap-functionalized liposomes 
Due to the adhesive nature of Eap, functionalization of liposomes with Eap 
resulted on formation of clumps after the purification step which was needed to 
eliminate the unbounded protein and the excess of coupling reagents. Therefore, 
a sonication step was applied to restore liposomes physical characteristics. Eap-
functionalized liposomes containing colistin were subjected to a short stability 
study after sonication to ensure that liposomal suspension remain homogeneous 
in terms of size distribution and no clamps were formed again after storage . 
Colloidal parameters were monitored over a week at 4° C. 
3.6 In vitro cell experiments 
3.6.1 Cell culture 
Human Larynx Carcinoma cell line (HEp-2 cells) received from the group of Prof. 
Petra Dersch, collaboration partner at HZI Braunschweig, and Human Colonic 
Adenocarcinoma cell line (Caco-2 cells) HTB-37 Clone purchased from (ATCC, 
Germany) were cultured in 75 cm2 flasks. Roswell Park Memorial Institute 
medium (RPMI 1640) obtained from (Gibco Life technology, Germany), 
supplemented with 10% Fetal Calf Serum (Sigma Aldrich, Germany) was used 
for HEp-2 cells. While, Caco-2 cells were cultured in Dulbecco’s Modified Eagle 
Medium (Gibco Life technology, Germany) supplemented with 10% FCS and 1% 
Non-Essential Amino Acids Solution (NEAA) purchased from (Gibco Life 
technology, Germany). Cells were incubated at 37° C, 5% CO2, and 95% 
humidification. Cells were splitted once a week when reaching confluence and 
the medium was changed every second day. 
3.6.2 Cytotoxicity assessment 
A colorimetric assay was used to evaluate the cell metabolic activity after 
liposomes application on both cell lines in order to assess the cytotoxicity of the 





formulations. MTT assay based on the ability of cells to reduce the reagent 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide to its purple insoluble 
form formazan was used (Figure 3.7). Viable cells number is therefore 
proportional to the amount of formazan detected at 550 nm wavelength (Riss et 
al. 2004). 
HEp-2 cells and Caco-2 cells were seeded on 96-well plates at a density of 
10.000 cell/well and 20.000 cell/well respectively prior the assay for two days. 
Cells were washed with Hank’s Balanced Salt Solution (HBSS) (Gibco Life 
technology, Germany) two times and then incubated with different concentrations 
of colistin, empty liposomes, colistin-loaded liposomes and Eap-functionalized 
liposomes containing colistin at 37° C, 5% CO2 for 4 h. Cells were washed 
afterwards with HBSS again two times and then MTT reagent was added to a 
final concentration of 1 mg/mL. After 4 h incubation, the reagent was removed 
and cells were incubated 15 min with dimethyl sulfoxide (DMSO) at 37° C in order 
to dissolve formazan crystals. The absorbance was measured at 550 nm using a 
plate reader (Tecan Trading AG, Switzerland). Determination of cell viability was 
calculated by setting Triton X-100 treated cells as 0% viability and cells without 
particle treatment were set as 100% viability. 
 
Figure 3.7. MTT assay principle 
The MTT reagent is reduced in living cells to an insoluble purple compound, 
which will be solubilized and analyzed with spectrophotometer at 550 nm. 
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3.6.3 Uptake efficiency 
Evaluation of the efficiency of Eap to facilitate the internalization of liposomes 
was investigated on epithelial cells of HEp-2 and Caco-2 cell lines. HEp-2 cells 
were chosen for this studies as they possess the β1 integrin receptors that 
InvA497 uses to mediate the internalization of Yersinia species into eukaryotic 
cells. Since, Caco-2 cells express these receptors only on the basolateral side, 
HEp-2 cells will be used as a comparison platform to evaluate the internalization 
efficiency of Eap versus InvA497. Cells were treated with liposomes for two 
different time points using different Eap concentrations and then flow cytometry 
BD LSRFortessa™ (Biosciences, Germany) was used to analyze samples and 
determine the binding and uptake efficiency. 
 HEp-2 cells 
Cells were seeded two days prior the experiment day in 24-well plate, at a density 
of 2 x 104 cells/ well and incubated in humidifier incubator at 37° C and 5% CO2. 
Cells were washed two times with PBS and 0.5 mL of fresh RPMI medium 
supplemented with 10% FCS and incubated with liposomes (Colistin-loaded 
liposomes functionalized with 5, 10 and 20 µg/mL Eap and non-functionalized 
liposomes as a control). After 1 h and 2 h incubation time, cells were washed 
again with PBS two times and then 0.1 mL of trypsin was added to detach the 
cells for 10 min at 37° C. A 0.3 mL of flow cytometer buffer (FACS buffer) 
composed of PBS containing 5% FCS, was added to inhibit trypsin activity and 
dilute the samples. Cell samples were analyzed freshly with flow cytometry (BD 
LSRFortessaTM Cell Analyzer Biosciences, Germany) and 10000 events per each 
sample were analyzed. FlowJo software (FlowJo 7.6.5, FlowJo LLC, USA) was 
used to analyze the data and uptake values were normalized to untreated cells 
(blank). 
 Caco-2 monolayer 
Caco-2 cells are the common used model in research for the intestinal epithelial 
barrier, therefore uptake studies were also performed with this cell line. As a 
model, Caco-2 cells were cultivated as a monolayer which is characterized by the 





formation of tight junctions. Cells were seeded on Transwell inserts of 0.4 µm 
pore size (Corning Incorporated, USA) at a density of 6 x 104 cells/well in 12-well 
plate. Cells were supplied with 0.5 mL DMEM supplemented with 10% FCS and 
1% NEAA solution on the apical compartment and 1.5 mL on the basolateral 
compartment, and medium was changed every second day. Cells with TEER 
values ≥ 500 Ω * cm2, were washed with PBS two times were incubated with 
different concentrations of Eap-functionalized liposomes (Eap: 5, 10 and 20 
µg/mL) as well as controls including cells without treatment (blank) and non-
functionalized liposomes. After incubation time of 2 h and 4 h, cells were washed 
two times with PBS, trypsinized with 0.1 mL for 10 min at 37°C and 0.4 mL of 
FACS buffer was added afterwards. Flow cytometer was used to analyze 10000 
event per sample each in triplicate. Data were analyzed as described above with 
HEp-2 cells). 
3.6.4 TEER measurements 
The barrier integrity of the monolayer was monitored over time via Transepithelial 
Electrical Resistance (TEER) measurements of cellular monolayer using 
epithelial volt-ohmmeter (World Precision Instruments, USA) equipped with 
chopstick electrodes. Electrical resistance measurement is a quantitative method 
based on the determination of the ohmic resistance by an application of a direct 
current voltage to the electrodes and measurement of the resulting current using 
the setup shown in (Figure 3.8). Briefly, cellular monolayer cultivated on 
semipermeable filter inserts which defining the partition for apical and basolateral 
compartments. The placement of an electrode in the upper compartment and the 
other in the lower compartment, allows for measuring the tissue resistance 
expressed in (Ω), where the resistance is inversely proportional to the effective 
area of the insert membrane expressed in (cm2). The procedure includes also the 
blank resistance determined by measuring the semipermeable insert filter without 
cells. The electrical resistance is then calculated by subtracting the blank inserts 
value (equal to 110 Ω) from all samples, and further multiplied by the cultivation 
area of the inserts (equal to 1.12 cm2) (Haorah et al. 2008; Watson et al. 2013). 
TEER measurements were taken every second day of the culture over time. 






Figure 3.8. TEER measurement setup 
Electrical resistance values were measured using chopstick electrodes, placed in 
the apical and another in the basolateral compartments separated by the cellular 
monolayer cultured on semipermeable insert filter. 
3.6.5 Cell Imaging 
For cell imaging, confocal laser scanning microscopy (CLSM Leica TCS SP 8, 
Leica, Germany) was used. Cells were seeded in 24-well plate with a transparent 
bottom two days before the experiment. On the experiment day, cells were 
incubated with liposomes (Eap-functionalized liposomes, non-functionalized 
liposomes and non-treated cells as a control) for 2 h (HEp-2 cells) and 4 h (Caco-
2 cells). Cells were washed with PBS two times and further incubated with 10 
µg/mL fluorescein-labeled wheat germ agglutinin (Flu-WGA) for 15 min at 37° C 
to stain the cell membrane. Cells were washed with PBS two times and then 
incubated with 3% of paraformaldehyde (PFA) for 30 min at room temperature 
for fixation. Cell nucleus was stained with 1 µg/mL of 4′, 6-Diamidin-2-phenylindol 
(DAPI) for 15 min at room temperature. Cells were washed again to remove 
excess of DAPI and 0.3 mL of PBS was added to keep cells humidified. 
Visualization was acquired using either 25x water immersion or 40x oil immersion 












rhodamine-labeled liposomes, Flu-WGA (cell membrane) and DAPI (nucleus) 
respectively. All images were acquired at 1024 X 1024 resolution and further 
processed with LAS X software (LAS X 1.8.013370, Leica Microsystems, 
Germany). 
3.6.6 Immunostaining of Caco-2 monolayer 
Caco-2 cells used as a model of the GI tract, which under normal conditions it 
acts as a cellular barrier to prevent the influx of the luminal content. This barrier 
is reinforced by multiprotein junctional complexes known as zonulae occludentes 
(ZO) (Anderson and van Itallie 2009). To visualize the integrity and the tightness 
of Caco-2 monolayer, an immunostaining of ZO-1, a tight junction associated 
protein, present on the cytoplasmic surface, was performed. Caco-2 monolayer 
were washed with PBS three times, and then fixed with PFA (3%) for 30 min at 
room temperature. After removing PFA, cells were incubated with a solution of 
50 mM NH4Cl for 1 h as a quenching solution. Afterwards, a solution of Saponin 
(0.05%) and bovine albumin serum (BSA) (1%) was added for 1 h at RT after 
removal of the quenching solution. Cells were washed with PBS again two times 
then incubated with primary antibody ZO-1, mouse (diluted 1:400 in Saponin / 
BSA solution) at 4° C overnight. Next day, cells washed three times with PBS, 
were incubated with a secondary antibody Alexa 488 anti-mouse (1:400 dilution 
in Saponin/BSA) for 2 h at room temperature. After washing with PBS three times, 
a nuclear staining using DAPI (as described above) and an actin filament staining 
using Phalloidin (30 min at RT) were performed. Transwell inserts were mounted 
on microscopy slides using DAKO mounting medium (Agilent Technologies, 
USA) and visualized with CLSM. 
3.6.7 Uptake mechanism 
A preliminary uptake mechanism experiment was performed at 4° C to determine 
whether HEp-2 and Caco-2 monolayer take up Eap-functionalized liposomes via 
a passive or an active pathway. Briefly, HEp-2 cells seeded on 24-well plate and 
Caco-2 monolayer on Transwells inserts exhibiting  TEER values ≥ 500 Ω * cm2 
as described previously (Section 3.6.3) were incubated with Eap-functionalized 





liposomes at 4° C for 2 h and 4 h respectively. Afterwards, cells were washed 
with PBS three times, trypsinized and further analyzed with flow cytometry.  
Further investigation of involved uptake mechanisms was conducted with Caco-
2 monolayer in which cells were subjected to an uptake experiment in which 
pharmacological endocytosis inhibitors were applied. Cells, seeded on 
Transwells inserts (with TEER values ≥ 500 Ω * cm2) were washed with PBS 
three times, and Hank's Balanced Salt Solution (HBSS) was added to apical as 
well as basolateral compartments containing different inhibitors (Figure 3.9) for 
1 h at 37° C. Cells were incubated with chlorpromazine (10 µg/mL) to inhibit 
clathrin-dependent endocytosis, cytochalasin D (1 mg/mL) for the inhibition of 
macropinocytosis, filipin III (1 µg/mL) to inhibit caveolin-dependent endocytosis 
and methyl-β-cyclodextrin (MβCD) / lovastatin (10 mM/1 µg/mL) for the inhibition 
of clathrin- and caveolin-independent endocytosis pathways (Alexander et al. 
2010; Zhang et al. 2014). Afterwards, liposomes were added to the upper 
compartment in the presence of inhibitors as well for another 2 h at 37° C and 5% 
CO2. Cells were washed with PBS, trypsinized and further analyzed with flow 
cytometry.  






Figure 3.9. Uptake mechanism pathways 
Illustration demonstrating different endocytosis pathways including 
macropinocytosis, clathrin-dependent endocytosis (Clathrin-DE) , caveolin-
dependent endocytosis (Caveolin-DE) and clathrin- and caveolin-independent 
pathways (clathrin- and caveolin-IDE), as well as their corresponding inhibitors 
cytochalasin D, chlorpromazine, filipin III and methyl-β-cyclodextrin 
(MβCD)/lovastatin respectively.  
3.7 In vitro infection studies 
Bacterial strain Salmonella enterica subsp. enterica (ex Kauffmann and Edwards) 
Le Minor and Popoff serovar Typhimurium 14028™ was reconstituted from a 
lyophilized vial stored at -80° C purchased from (ATCC®, USA). Bacterial cultures 
were prepared by growing the bacteria in Difco™ Nutrient Broth (BD, USA) for 18 
h at 37° C. a stock solution of S. enterica was prepared by adding 5% Glycerol 
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3.7.1 Bacterial growth curve 
A growth study of S. enterica was conducted by incubating an optical density 
(OD) of 0.01 from an overnight culture of single colony in several overnight glass 
tubes containing 5 mL of Nutrient Broth over 24 h at 37° C. Samples were taken 
at each time point and their OD was measured and 1 mL from each sample was 
collected and stored at -20° C. After collections of all time point, samples (stored 
previously at -20° C, were subjected to a serial dilution in Nutrient Broth to 10, 
102, 103, 104, 105, 106, 107, 108, 109 and 1010. Afterwards, only dilutions 104, 106, 
108, and 1010 were plated on Nutrient agar plates and incubated overnight at 37° 
C for 18 h. Salmonella colonies were counted for each time point the number was 
expressed as Colonies Forming Unit (CFU)/mL. 
3.7.2 Minimum inhibitory concentration (MIC) 
Salmonella was cultured overnight in glass tubes containing 5 mL Nutrient Broth 
for 18 h at 37° C. A dilution from the overnight culture to an OD600 of 0.1 was 
prepared in 96-well plate, 100 µL in each well. Colistin as free drug, liposomes 
functionalized and non-functionalized with Eap were diluted to several 
concentrations separately two times higher than the desired concentration. 
Afterwards, 100 µL from each sample was added to each well and mixed gently 
with the pipette up and down. Wells containing Nutrient Broth was used as blank. 
The OD600 of each samples was measured after preparation (T0) and then 
incubated at 37° C for 18 h. A measurement of the OD600 was performed after 
the incubation and MIC values were calculated by normalizing samples OD600 
values to the non-treated samples (only bacteria in Nutrient Broth). IC50 and IC90 
values were considered as the lowest concentration of samples, which reduced 
at least 50% and 90% of the bacterial load respectively were determined using 
OriginPro software (OriginLab Corporation, USA). 
3.7.3 Anti-bacterial efficacy 
 Optimization of the infection assay 





HEp-2 cells were seeded in 24-well plate one day prior the experiment at a 
density of 1 x 105 cells/well as described previously (Menina et al. 2016). Caco-2 
monolayer were seeded on Transwell inserts in 12-well plate at a density of 6 x 
104 cells/well for 7 days to reach TEER values of ≥ 500 Ω * cm2. An overnight 
culture of Salmonella was centrifuged at 350 g for 5 min, Nutrient Broth was 
aspirated and bacterial pellet was re-suspended in PBS for washing. 2 cycles of 
washing were performed and bacteria were re-suspended further in the infection 
buffer composed of either RPMI medium (HEp-2 cells) or DMEM (Caco-2 cells) 
supplemented with 20 mM Hydroxyethyl-piperazineethane-sulfonic acid buffer 
(HEPES buffer, Biochrom, Germany) and 0.4% BSA.  
HEp-2 and Caco-2 monolayer were washed two times with PBS, and fresh 
infection buffer was added. Cells were infected with different Multiplicity of 
infection (MOI) 10, 25, 50, and 100 (number of bacteria per one host cell) and 
incubated with Salmonella for 1 h at 37° C and 5% CO2. After incubation, cells 
were washed with PBS two times, and extracellular bacteria were killed by 
incubating cells for further 2 h with 50 µg/mL of gentamicin solution. Cells were 
then washed 2 times with PBS and further lysed with ice-cold water for 10 min. 
Cell lysates were plated on Nutrient agar plates with different dilutions (104, 106, 
108, and 1010) (Figure 3.10). Plates were incubated at 37° C for 18 h and bacterial 
colonies were counted, multiplied with dilution factor and expressed as infection 
percentage using the following formula: 
Equation 4. Infection percentage 
𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛 (%) =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑙𝑦𝑠𝑎𝑡𝑒
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑜𝑓 𝑖𝑛𝑜𝑐𝑢𝑙𝑢𝑚
 × 100 
 






Figure 3.10. Optimization of infection assay 
(1) Cells were infected with different MOI of Salmonella for 1h then (2) gentamicin 
solution (50 µg/mL) was added to kill extracellular bacteria for 2 h. (3) Cells were 
lysed and the cell lysates containing intracellular Salmonella were plated on agar 
plates and incubated for 18 h at 37° C and 5% CO2. Light microscope images on 
(1 and 2) showed HEp-2 cells after washing with PBS and after applying 
Salmonella respectively 
 Killing efficacy assay  
Infection protocol was performed as described above (Section 3.7.3). Briefly, 
after infection of cells with Salmonella (MOI of 100) for 1 h and extracellular 
bacterial killing for 2 h, HEp-2 and Caco-2 monolayer were treated with different 
liposomal formulations for 2 h and 4 h respectively and incubated at 37° C and 
5% CO2. Unloaded liposomes (Lip-3), colistin-loaded liposomes (Col-Lip-3), Eap-
functionalized liposomes containing colistin (EapCol-Lip-3) were used to treat the 
cells, colistin as free drug (Col) as well as Eap added directly without any 
functionalization of prior adsorption to colistin as free drug (Col + Eap) and to 
colistin-loaded liposomes (Col-Lip-3 + Eap) were used as controls. After 
liposomal treatment, cells were washed with PBS two times, and lysed with ice-
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(Figure 3.11) and incubated at 37° C and 5% CO2. Anti-bacterial efficiency was 
expressed as killing percentage of normalized samples CFU/mL values to the 
control (untreated sample). 
 
Figure 3.11. Antibacterial efficacy protocol 
(1) Cells were infected with Salmonella with an MOI of 100, (2) the extracellular 
Salmonella was killed using gentamicin solution of 50 µg/mL. Salmonella-infected 
HEp-2 cells and Caco-2 monolayer were treated with liposomal formulations as 
well as controls for 2 h or 4h respectively. (4) Cells were lysed to extract 
intracellular bacteria, which were plated on agar plates and incubated for 18 h at 
37°C and 5% CO2. 
3.7.4 Colistin dose-response and Eap titration studies 
Colistin dose-response experiment was performed by treating HEp-2 and Caco-
2 monolayer with different doses of colistin-loaded liposomes (10, 30, 50, 80, 150 
and 200 µg/mL) functionalized initially with 20 µg/mL Eap and loaded with 4 
mg/mL colistin (as described previously in Section 4.2). Eap titration study was 
conducted by incubation HEp-2 cells and Caco-2 monolayer with colistin-loaded 
liposomes containing 30 µg/mL of colistin dose and functionalized with different 
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37°C and 5% CO2. The infection and treatment protocols were performed as 
previously described in Section 3.7.3.  
3.8 In vivo assessment of anti-infective efficacy 
A pilot study was carried out by the group of Prof. Dr. Till Strowig at the Microbial 
Immune Regulation Department, Helmholtz Centre for Infection Research (HZI) 
in Braunschweig. The aim of this in vivo study was to investigate the efficacy of 
the developed system; Eap-functionalized liposomes containing colistin to 
eradicate the enteroinvasive bacterium Salmonella enterica in a mouse model (
 
Figure 3.12). Briefly, mice were divided into four groups each group consists of 
five mice treated prior the infection day with streptomycin to decrease the 
colonization resistance. Salmonella Typhimurium strain SL1344, was used to 
infect the mice. After 6 h animals were treated with 1 mg dose of colistin either 
encapsulated into EapCol-Lip-3 or InvCol-Lip-3; or as free drug via oral gavage, 
PBS was used as control. After 18 h, the mice were weighed and then sacrificed. 
Small intestine and cecum were recovered, washed and the resulted suspension 
was plated on agar plates to obtain CFU in content, and then the tissues were 
homogenized and plated on agar plates to obtain CFU in tissue. Results were 
expressed as CFU/g. 
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Figure 3.12. Experimental plan of the in vivo study 
Animals were subjected to a pre-treatment with antibiotics 24 h prior the infection, 
afterwards, they were infected using S. Typhimurium strain SL1344 for a period 
of 6 h. Liposomal treatment was administrated via oral gavage (EapCol-Lip-3 and 
InvCol-Lip-3) as well as free colistin free and PBS as controls. CFU in content 
and in tissue were counted after 18 h from the treatment. 
3.9 Statistical analysis 
All data are shown as mean ± standard error of the mean (SEM) from at least 
three independent experiments. One-way Anova followed by post hoc analysis 
was used to calculate the statistical significance using OriginPro software 
(OriginLab Corporation, USA). Differences were considered to be significant at 
P-value < 0.05 (*), < 0.01 (**) and < 0.001 (***).  
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Parts of these results section were published in Advanced Healthcare Materials 
Journal, in 2018 (https://doi.org/10.1002/adhm.201900564), included in the 
following chapters: Colistin-loaded liposomes characterization and Morphology, 
Stability studies for oral route, Eap-functionalized liposomes containing colistin, 
Eap mediates the binding/internalization of liposomes into epithelial cells and 
antibacterial efficacy of EapCol-Lip-3. 
4.1 Unloaded liposomes  
4.1.1 Colloidal characterization 
Three liposomal formulations were prepared using DPPC, DSPC and 
DPPC:DSPC separately as main phospholipids. These formulations contained 
also cholesterol for rigidity and DPPE-GA to provide the liposomal surface with 
carboxylic group for facilitating their functionalization. For better understanding of 
liposomal internalization and tracking their delivery pathways, Rhod-DPPE was 
implemented into liposomal composition which label them with a red 
fluorescence. All three formulations exhibited a size of approximately 200 nm, 
with a homogeneous distribution reflected by PDI values lower than 0.1 
(Figure 4.1 a, b). Moreover, a negative charge of -28 mV and -25 mV for DPPC- 
(Lip-1) and DSPC-containing liposomes (Lip-2) respectively was measured, while 
a less negative ζ-potential value (-19 mV) was measured with DPPC/DSPC 
formulation (Lip-3) (Figure 4.1 c). 
4.1.2 Unloaded liposomes stability 
Lip-1, Lip-2 and Lip-3 were subjected to different stability studies, in which 
colloidal parameters size, PDI and surface charge were monitored in various 
conditions including storage, impact of pH and impact of bile salts/phospholipids 
presence on their integrity over time. Samples were taken from prepared 
liposomes stored at 4° C every one week during one month period. Results 
showed that Lip-1, Lip-2 and Lip-3 were stable in suspension at 4° C and no 





notable changes were seen in all parameters (Figure 4.2 a, b, c). Incubation of 
liposomes in PBS (pH 7.4) as buffer control (B), buffer of pH 6.5 and a buffer of 
pH 1.6 as well as in simulated media FaSSGF and FaSSIF at 37° C for 5 h period, 
resulted in a stable size of approximately 200 nm except in FaSSIF –where the 
size of all liposomes decreased to approximately 100 nm (Figure 4.2 d). 
 
Figure 4.1. Colloidal characteristics of unloaded liposomes 
(a) Size, (b) PDI and (c) ζ-potential of unloaded liposomes Lip-1 
(DPPC:CHOL:DPPE-GA), Lip-2 (DSPC:CHOL:DPPE-GA) and Lip-3 
(DPPC:DSPC:CHOL:DPPE-GA) measured after preparation (day 0). Data are 
shown as mean ± SEM from three independent experiments (n= 3, N= 9, as “n” 
is number of independent experiments and “N” is number of repetitions). 
A slight increase of PDI was observed in pH 1.6 buffer and in FaSSGF, while a 















































to -20 mV were measured in all media; however lower values with all three 
formulations were observed in FaSSIF (-27 to -28 mV) (Figure 4.2 f). 
 
Figure 4.2. Unloaded liposomes stability  
(a) Size, (b) PDI and (c) ζ-potential of unloaded liposomes Lip-1, Lip-2 and Lip-3 







































































and (f) ζ-potential of liposomal formulation after incubation for 5 h in PBS (pH 7.4, 
B) buffer pH 6.5, buffer pH 1.6, gastric (FaSSGF) and intestinal simulated media 
(FaSSIF) at 37° C. Data are shown as mean ± SEM from three independent 
experiments (n= 3, N= 9). 
4.2 Colistin-loaded liposomes 
Colistin was encapsulated into the above formulated liposomes Lip-1, Lip-2 and 
Lip-3 since no major differences were observed between the formulations after 
stability studies. Preparation of colistin-loaded liposomes Col-Lip-1, Col-Lip-2 and 
Col-Lip-3 was conducted using lipid film hydration method, in which the hydration 
of the lipid film was done with colistin solution in PBS using different 
concentrations (1, 2, 3, 4, 5, 10 mg/mL) aiming to obtain an optimum liposomal 
formulation which exhibits a high entrapment efficiency as well as an optimum 
loading capacity. 
4.2.1 Colloidal characterization 
Col-Lip-1, Col-Lip-2 and Col-Lip-3 were characterized in terms of size, PDI and 
surface charge. Results did not show significant changes in size and PDI 
compared to unloaded liposomes. Homogeneously distributed spherical-shaped 
vesicles of 200 nm (Figure 4.3 a) were observed except Col-Lip-1 prepared with 
10 mg/mL of colistin showed a PDI of 0.15 (Figure 4.3 b). Regarding liposomal 
surface charge, a decrease of ζ-potential values in a range of -12 mV to -23 mV 
was observed, which was expected as colistin exhibits a positive charge. Col-Lip-
2 exhibited higher negative charge compared to the other two formulations 
(Figure 4.3 c).  






Figure 4.3. Colloidal parameters of colistin-loaded liposomes 
(a) Size, (b) PDI and (c) ζ-potential of Col-Lip-1, Col-Lip-2 and Col-Lip-3 loaded 
with 1, 2, 3, 4, 5 and 10 µg/mL of colistin. Samples were measured immediately 
after preparation. Data are shown as mean ± SEM from three independent 
experiments (n= 3, N= 9). 
4.2.2 Liposomes morphology 
Electron microscopy imaging was conducted to investigate liposomal morphology 
of Col-Lip-1, Col-Lip-2 and Col-Lip-3. SEM image of Col-Lip-1 showed a 
homogenous distribution of 200 nm spherical vesicles (Figure 4.4 a). No 
difference was detected between formulations in all imaging techniques; 






















































image. TEM imaging also showed a spherical-shaped liposomes with a presence 
of small impurities in the background, which could be due to the staining solution 
which was used to increase the contrast of the electron beam and enhance the 
imaging (Figure 4.4 b). The advantage of Cryo-TEM imaging is that the sample 
needs no pre-treatment like staining, washing of buffer salts, drying, which both 
SEM and TEM require. Col-Lip-3 image showed nicely spherical vesicles of about 
200 nm (Figure 4.4 c). 
 
Figure 4.4. Liposomes morphology 
Representative microscopy images of Col-Lip-1 visualized using SEM (a) and 
TEM (b) techniques and of Col-Lip-3 using Cryo-TEM (c), indicating the presence 
of spherical liposomes with homogeneous size distribution as shown in SEM 
image. 
4.2.3 Colistin loading 
Col-Lip-1, Col-Lip-2 and Col-Lip-3 were subjected to further characterization 












amount of colistin encapsulated into liposomes was approximately 60% using 1 
mg/mL of colistin for the three liposomal formulations. However, the EE% values 
decreased by increasing colistin concentration with also differences between the 
different formulations where the lower value was 20%, obtained using 10 mg/mL 
colistin loaded into Col-Lip-1 (Figure 4.5 a). On the other hand, the loading 
capacity increased by increasing colistin concentrations, starting with 20% in the 
three liposomes and increased to 80% using 10 mg/mL of colistin (Figure 4.5 b).  
 
Figure 4.5. Colistin-loaded liposomes properties  
The entrapment efficiency (a), loading capacity (b) of Col-Lip-1, Col-Lip-2 and 
Col-Lip-3 loaded with different concentrations of colistin (1, 2, 3, 4, 5 and 10 
mg/mL). Data are shown as mean ± SEM from three independent experiments 
(n= 3, N= 9). 
After comparison of the obtained data for each formulation (Col-Lip-1, Col-Lip-2 
and Col-Lip-3) with each concentration (1, 2, 3, 4, 5 and 10 mg/mL), we decide 
to use 4 mg/mL as standard colistin concentration for the three liposomal 
formulations. This decision was based on the fact that 4 mg/mL was the optimal 
compromise between the EE and LC. Moreover, it showed no-to-low differences 
between the three formulations. Afterwards, an optimization of the preparation 
process was performed in order to achieve higher entrapment efficiency and 






































Table 4. Characteristics of colistin-loaded liposomes (4 mg/mL) after 
optimization 




211.8 ± 1.7 
201.3 ± 1.0 
202.7 ± 1.4 
0.05 ± 0.1 
0.05 ± 0.1 
0.03 ± 0.1 
-21.0 ± 0.6 
-17.3 ± 0.3 
-15.3 ± 1.2 
55.3 ± 5.2 
61.7 ± 5.7 
59.3 ± 4.3 
49.8 ± 0.4 
50.9 ± 0.7 
50.4 ± 0.3 
 
4.3 Stability studies for the oral route 
Stability of liposomes in storage conditions (at 4° C) over time did not show major 
changes in terms of colloidal properties for all liposomes, except Col-Lip-1 
containing 2 mg/mL and 10 mg/mL of colistin, showed an increase in size to 300 
nm after 15 days (Figure 4.6 a). However, the size decreased to 200 nm during 
the two following weeks. The increase in size of the two formulations was 
accompanied with an increase in PDI from 0.08 and 0.12 to 0.25 and 0.24 
respectively, and a PDI values ranging from 0.03 to 0.15 were observed with 
other concentrations (Figure 4.6 b). Similar pattern was observed with Col-Lip-2 
loaded with 3 mg/mL of colistin after one week and loaded with 2 mg/mL after 3 
weeks (Figure 4.6 d, e). While, Col-Lip-3 containing 3 mg/mL of colistin exhibited 
a size of 300 nm after preparation and showed some size fluctuations each week 
to reach approximately 200 nm in the fourth week (Figure 4.6 g, h). In all cases, 
no notable changes in surface charge were seen during the tested period 
(Figure 4.6 c, f, I for Col-Lip-1, Col-Lip-2 and Col-Lip-3 respectively).  






Figure 4.6. Stability characteristics of colistin-loaded liposomes 
Size, PDI and ζ-potential values of Col-Lip-1 (a, b and c), Col-Lip-2 (d, e and f) 
and Col-Lip-3 (g, h and i) loaded with 1, 2, 3, 4, 5 and 10 mg/mL of colistin. 
Measurements were taken every week after preparation over 4 weeks. Data are 
shown as mean ± SEM from three independent experiments (n= 3, N= 9). 
Colloidal parameters of Col-Lip-1, Col-Lip-2, and Col-Lip-3 after incubation in 
FaSSGF and FaSSIF showed an optimum stability after 5 h in terms of size and 
PDI without major changes between both simulated media compared to the 
control (PBS) (Figure 4.7). While, their incubation in FaSSIFEnz (which contains 
lipase, protease and amylase) resulted in a dramatic increase in size (>600 nm) 
(Figure 4.7 a) with heterogeneous size distribution indicated by PDI values ≥ 0.4 







































































































































resulted in particles with a slight increase of size compared to control of 
approximately 250 nm, 210 nm and 350 nm respectively. Moreover, a 
polydispersity of particles was also observed especially with Col-Lip-1 and Col-
Lip-3 (PDI ≥ 0.4), while a PDI of 0.3 was measured for Col-Lip-2. Regarding the 
surface charge, in FaSSGF, an increase from -12 mV to -23 mV (Col-Lip-1), from 
-18 mV to -22 mV (Col-Lip-2) and from -9 mV to -18 mV (Col-Lip-3) was observed. 
However, these values followed a decreasing pattern in FaSSIF and FaSSIFEnz 
reaching values below -10 mV for all the formulations (Figure 4.7 c). On the other 
hand, ζ-potential values for all the liposomes increased to -30 mV after incubation 
in FeSSIF. These results indicate that the lower pH of FaSSGF had mainly effect 
on the ζ-potential; enzymes addition to intestinal simulated fluid caused the 
largest change in size/size distribution. While, high concentration of salts and 
phospholipids in FeSSIF had an effect on size distribution and charge. 






Figure 4.7. Colloidal characteristics in simulated media 
(a) Size, (b) PDI, and (c) ζ-potential of Col-Lip-1, Col-Lip-2 and Col-Lip-3 after 
incubation in different simulated media (FaSSGF, FaSSIF, FaSSIFEnz and 
FeSSIF) and PBS as a control. The experiment was conducted at 37° C for 5 h. 
Data are shown as mean ± SEM from three independent experiments (n= 3, N= 
9). 
Colistin retention results over 5 h incubation in simulated media are shown in 
Figure 4.8. All liposomal formulations showed a release of less than 4 % in PBS. 
However, a burst release reaching a maximum of 20% was detected after 
incubation of Col-Lip-1 in all biorelevant media with a colistin retention of 















































release of ≤60% was detected in FeSSIF (Figure 4.8 a). While, a retention of 
≥80% of colistin was seen after incubation of Col-Lip-2 (Figure 4.8 b) and Col-
Lip-3 (Figure 4.8 c) in all simulated media characterized with a slower release 
compared to Col-Lip-1. After analysis and comparison of the obtained data, only 
Col-Lip-2 and Col-Lip-3 were carried for further experiments due to the instability 
of Col-Lip-1. 
 
Figure 4.8. Colistin release kinetics in simulated media 
Released amount of colistin from Col-Lip-1 (a), Col-Lip-2 (b) and Col-Lip-3 (c) 
after incubation in different media (FaSSGF, FaSSIF, FaSSIFEnz and FeSSIF) in 
comparison to control (PBS) after 5 h test period and incubation at physiological 
temperature (37° C). Released amount at each time point was normalized to the 
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the incubation. Data are shown as mean ± SEM from three independent 
experiments (n= 3, N= 9). 
4.4 Eap-functionalized liposomes containing colistin 
Liposomes loaded with colistin (Col-Lip-2 and Col-Lip-3) were functionalized with 
Eap using different methods, including covalent coupling (Cov) using either 
EDC/NHS or DMTMM reagents or physical adsorption (Phy) achieved by a direct 
incubation of liposomes with Eap. Quantification of coupled and/or adsorbed Eap 
on liposomal surface was not possible using common proteins quantification 
assays such as BCA assay or Bradford assay due to the interference of 
polypeptide “colistin”, therefore SDS-PAGE was used to estimate the 
approximate amount of Eap on liposomal surface. Results showed clear Eap 
bands around 55 kDa with all Eap-functionalized liposomes and no detectible 
bands with non-functionalized liposomes, indicating the successful coupling 
and/or adsorption of Eap on liposomal surface (Figure 4.9 a). Regarding the 
functionalization efficiency, covalent linking using EDC/NHS lead only to 37% of 
functionalization efficiency for EapCol-Lip-2 and 44% for EapCol-lip-3 (Figure 4.9 
b). Covalent coupling using DMTMM reagent lead to approximately 39% and 57% 
functionalization efficiency for EapCol-Lip-2 and EapCol-Lip-3 respectively, while 
incubation of Eap with liposomes for physical surface adsorption lead to a FE of 
approximately 53% for EapCol-Lip-2 and 74% for EapCol-Lip-3 (Figure 4.9 b).  
Eap coupled via surface adsorption on EapCol-Lip-3 surface showed the highest 
FE; therefore, only this formulation was carried further to investigate uptake 
kinetics and antibacterial efficacy. 






Figure 4.9. Functionalization efficiency 
(a) SDS-PAGE of Eap standards (5, 10, 20, 30, 40 and 50 µg/mL), non-
functionalized liposomes (Col-Lip-2 and Col-Lip-3) and Eap-functionalized 
liposomes (EapCol-Lip-2 and EapCol-Lip-3). (b) Functionalization efficiency of 
EapCol-Lip-2 and EapCol-Lip-3 calculated using Image J. Liposomes were 
functionalized with Eap either covalently [Cov (DMTMM) and Cov (EDC/NHS)] or 
physically via adsorption on liposomal surface (adsorption). Data are shown as 
mean ± SEM from three independent experiments (n= 3, N= 9). 
Eap-functionalized liposomes were characterized also in terms of colloidal 
parameters, after functionalization. Results showed that the size as well as the 
PDI increased dramatically to ≥1000 nm and ≥0.7 respectively using both 
functionalization methods; covalent coupling [Eap (Cov)] or surface adsorption 
[Eap (Ads)] (Figure 4.10 a, b). This increase is caused by the aggregation of 
liposomes once interacting with Eap, since Eap is characterized with its adhesive 
properties (clear flakes were detected by eye after incubation of liposomes with 
Eap). Therefore, liposomes were subjected after functionalization to a sonication 
cycle, which lead to restoration of their initial size of approximately 200 nm with 
a PDI below 0.2. All liposomal formulations showed a surface charge of about -

























Figure 4.10. Colloidal characteristics of Eap-functionalized liposomes 
(a) Size, (b) PDI and (c) ζ-potential of colistin-loaded liposomes (Col-Lip-2 and 
Col-Lip-3) and sonicated-colistin-loaded liposomes (Sonic. Col-Lip-2 and Sonic 
Col-Lip-3) without functionalization [Eap (-)], Eap-functionalized via surface 
adsorption [Eap (Ads)] and Eap-functionalized via covalent coupling [Eap (Cov)]. 
Data are shown as mean ± SEM from three independent experiments (n= 3, N= 
9).  
Stability of sonicated liposomes was monitored over a short time period to ensure 
the stable state of particles after sonication process and investigate whether the 
presence of Eap will lead to a reversible aggregation effect (Figure 4.11). Results 
showed that liposomes were stable in terms of colloidal properties after sonication 
during the tested period and no major changes in size or PDI were detected 
(Figure 4.11 a, b). Regarding ζ-potential, the negative surface charge did not 
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mV to -20 mV after sonication but only with liposomes functionalized via surface 
adsorption was observed (Figure 4.11 c). Despite, the stability of Eap-
functionalized liposomes after sonication, it has been decided to use liposomes 
freshly functionalized and sonicated for further studies. 
 
Figure 4.11. Stability of Eap-functionalized liposomes 
(a) Size, (b) PDI and (c) ζ-potential of colistin-loaded liposomes functionalized 
with Eap subjected to two cycles of sonication using 50% amplitude for 30 
seconds each with an interval of 2 min (EapCol-Lip-2 and EapCol-Lip-3) in 
comparison to non-sonicated Eap-functionalized liposomes (no Sonic.). 
Functionalization was performed either via adsorption (Ads) or covalently coupled 
(Cov). Data are shown as mean ± SEM from three independent experiments (n= 
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4.5 In vitro cellular studies 
4.5.1 Intestinal barrier model 
Epithelial cells of the Caco-2 cell line, were used as a model for the intestinal 
cellular barrier. Cells were cultured on Transwells inserts with a semipermeable 
filters for 7 days to form tight junctions. TEER measurements taken every second 
day showed values < 200 Ω*cm2 during the first 5 days followed by an increase 
of the transepithelial resistance to reach 2000 Ω*cm2 on day 8 (Figure 4.12 a). 
Values ≥500 Ω*cm2 were considered as an indication of barrier formation. This 
barrier is characterized by the formation of tight junctions which was confirmed 
using an immunostaining of Zonula occludens-1 (ZO-1) at day 7. ZO-1 as a 
scaffold protein, called also tight junction protein-1, is a 220 kDa peripheral 
membrane protein that cross-links tight junction strand proteins located within 
lipid bilayer to the actin cytoskeleton. Immunofluorescence image showed nice 
formed tight junctions stained in green with red actin filaments (Figure 4.12 b). 
 
Figure 4.12. Caco-2 monolayer properties 
(a) Development of TEER for Caco-2 grown on Transwell inserts equipped with 
semipermeable filters. TEER measurements were taken every second day for a 
period of 8 days. Data are shown as mean ± SEM from three independent 
experiments (n= 3, N= 9). (b) Immunofluorescence staining of Caco-2 monolayer 


























filament stained in red using Phalloidin and nucleus in purple (red and blue) using 
DAPI.  
4.5.2 Cytotoxicity assessment 
The effect of liposomes application of on cell viability was investigated using MTT 
assay. Unloaded liposomes, colistin-loaded liposomes or Eap-functionalized 
liposomes containing colistin were tested using three different liposome 
concentrations (15, 120 and 750 µg/mL) which covers the concentrations of 
liposomes used for all cell-based assays. Colistin as free drug as well as Eap 
were also tested on HEp-2 cells and Caco-2 monolayer as controls and 
incubation was defined as 4 h for all samples. Colistin concentrations from 1 
µg/mL to 500 µg/mL did not show any toxicity on HEp-2 cells (Figure 4.13 a) 
neither on Caco-2 monolayer (Figure 4.13 b), except the 1 mg/mL colistin 
concentration showed a 50% cell death of HEp-2 cells whereas no effect was 
seen with Caco-2 monolayer using same concentration. On the other hand, 
incubation of HEp-2 cells (Figure 4.13 c, e) and Caco-2 monolayer (Figure 4.13 
d, f) with Lip-2, Lip-3, Col-Lip-2, Col-Lip-3, EapCol-Lip-2 and EapCol-Lip-3 did 
not show any notable cytotoxicity within tested range of concentrations. 






Figure 4.13. Cytotoxicity results 
HEp-2 cells and Caco-2 cells were incubated with colistin (a, b), unloaded 
liposomes (Lip-2 and Lip-3), Colistin-loaded liposomes (Col-Lip-2 and Col-Lip-3) 
(c, d) and Eap-functionalized liposomes containing colistin (EapCol-Lip-2 and 

























































































































and 5% CO2. Data are shown as mean ± SEM from three independent 
experiments (n= 3, N= 9). 
4.5.3 Eap mediates the binding/internalization of liposomes 
into epithelial cells 
HEp-2 cells and Caco-2 monolayer were employed in this experiment to assess 
the ability of Eap to mediate the binding and the internalization of liposomes into 
the cells. Col-Lip-3 was used for the following studies and Eap functionalization 
was conducted using surface adsorption. Uptake of Col-Lip-3 by HEp-2 cells was 
negligible while incubation of Caco-2 monolayer with Col-Lip-3 induced 35% 
uptake (rhodamine-positive cells percentage determined using flow cytometry) of 
these nanocarriers (Figure 4.14 a, c respectively). On the other hand, application 
of EapCol-Lip-3 on HEp-2 cells as well as on Caco-2 monolayer, functionalized 
with different concentrations of Eap (5, 10 and 20 µg/mL) showed a 
concentration- and time-dependent uptake. After 1 h incubation of cells with 
EapCol-Lip-3 (5 µg/mL), only 5% of HEp-2 cells and 12% of Caco-2 cells showed 
a positive-rhodamine fluorescence, however increasing the incubation time to 2 
h showed a significant increase of the uptake efficiency of approximately 47% 
and 42% respectively (Figure 4.14 a, c). The use of 10 µg/mL Eap-functionalized 
Col-Lip-3 showed an uptake of 32% (and 45% by HEp-2 cells (1 h) and Caco-2 
cells (2 h) respectively, further incubation induced a significant increase of 
rhodamine-positive HEp-2 cells (2 h) and Caco-2 monolayer (4 h) to 99% and 
83% respectively as shown in Figure 4.14 a, b. Utilization of 20 µg/mL of Eap to 
functionalize liposomes showed an improvement of the uptake efficiency from 
88% to 99% by HEp-2 cells after 1 h and 2 h respectively, and from 76% to 97% 
by Caco-2 cells after 2 h and 4 h respectively. However, 2 h incubation time of 
Eap-Col-Lip-3 either with 10 µg/mL or 20 µg/mL by HEp-2 cells showed a 
saturation achieving almost 100% of rhodamine-positive cells. Flow cytometry 
histograms showed a clear gradually shift of EapCol-Lip-3 (with a concentration-
dependence) on the red fluorescence channel (PE) with both cell types HEp-2 
cells (2 h) and Caco-2 monolayer (4 h) compared to the control (without 
liposomes) (Figure 4.14 b, d). 






Figure 4.14. Uptake efficiency 
Percentage of rhodamine-positive HEp-2 cells (a) and Caco-2 cells (c) as well as 
a representative flow cytometry histograms of HEp-2 cells (2 h, c) and Caco-2 
cells (4 h, d) after incubation with non-functionalized Col-Lip-3 and EapCol-Lip-3 
functionalized with either 5, 10 or 20 µg/mL of Eap. Non-treated cells were used 
as a control. Data are shown as mean ± SEM from three independent 
experiments (n= 3, N= 9). Statistical difference is considered significant with P-
value < 0.05 (*), < 0.01 (**) and < 0.001 (***). 
Imaging of liposomal internalization into HEp-2 cells and Caco-2 monolayer was 
performed using CLSM. Cells were cultured either on 24-well plate with 
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afterwards on microscope slides (Caco-2 cells). Uptake study was performed as 
described in flow cytometry setup, in addition cell membrane was stained with 
Flu-WGA (green), nucleus with DAPI (blue) after fixation with paraformaldehyde 
and liposomes were labeled covalently with rhodamine (red) during preparation. 
Images showed no noticeable red fluorescent on HEp-2 cells after incubation with 
Col-Lip-3 (Figure 4.15 a), while, a detectable red fluorescence in Caco-2 cells 
indicating an uptake of Col-Lip-3 at some extent (Figure 4.15 b), which support 
the data obtained from the flow cytometry. On the other hand, application of 
EapCol-Lip-3 on HEp-2 cells (for 2 h, Figure 4.15 a) and Caco-2 cells (for 4 h, 
Figure 4.15 b), showed a high red fluorescence indicating higher uptake in 

































Figure 4.15. Uptake imaging 
Representative confocal images of Col-Lip-3 and EapCol-Lip-3 (functionalized 
with 20 µg/mL Eap) uptake by (a) HEp-2 cells (2 h) and (b) Caco-2 cells (4 h) in 
comparison to non-treated cells. Cell membrane was stained in green 
(Fluorescein), nucleus in blue (DAPI) and liposomes in red (rhodamine). Images 
were taken with 25x water immersion, using 533 nm, 488 nm and 720 nm 
excitation wavelengths for rhodamine-labeled liposomes, fluorescein (cell 
membrane) and DAPI (nucleus) respectively. 
A 3D imaging of uptake of EapCol-Lip-3 (functionalized with 20 µg/mL Eap) using 
HEp-2 and Caco-2 cells after 2 h and 4 h respectively was conducted (Figure S3 
in supplement), and results supported the 2D images taken in Figure 4.15 
showing a dominant red fluorescence in the red channel which can be also visible 
in merge picture. An Orth-view imaging with same setup was performed in order 
to visualize the localization of liposomes into the cells and investigate closely 































fluorescence in the same level as nucleus rather than on the level of cell 
membrane indicating that indeed liposomes were internalized into HEp-2 and 
Caco-2 cells (Figure S4). 
In order to understand the mechanism behind the internalization of Eap-
functionalized liposomes by HEp-2 cells and Caco-2 cells, an uptake experiment 
at 4° C was performed. The results of EapCol-Lip-3 uptake by HEp-2 cells 
showed a similar tendency to the uptake performed at 37° C (Figure 4.16 a). 
While, uptake of EapCol-Lip-3 by Caco-2 cells showed a significant decrease in 
rhodamine-positive cells percentage of approximately 18% compared to uptake 
at 37° C (Figure 4.16 a). Flow cytometry histograms showed a complete peak 
shift in PE channel (rhodamine/red fluorescence) in HEp-2 cells at 4° C, 
comparable to 37° C uptake kinetics. While, only a slight shift was seen in case 
of Caco-2 cells indicating an inhibition process of the uptake was accrued at 4°C 
in comparison to 37° C (Figure 4.16 b). These results indicated that the uptake 
mechanism of Eap in Caco-2 cells is an energy-dependent process whereas a 
passive pathway was the main characteristic of EapCol-Lip-3 uptake in HEp-2 
cells. 
A following experiment investigating deeply the mechanism of uptake in Caco-2 
cells using pharmacological endocytosis inhibitors was conducted. The results 
showed a decrease in the uptake efficiency of approximately 8% after using 
cytochalasin D, and a decrease of 17% using either chlorpromazine or MβCD + 
lovastatin. While, 40% of the uptake was inhibited in the presence of caveolin-
dependent endocytosis inhibitor “Filipin III” (Figure 4.16 c). 






Figure 4.16. Uptake mechanism kinetics 
(a) EapCol-Lip-3 uptake mechanism study on HEp-2 (2 h) and Caco-2 (4 h) cells 
at 4° C in comparison to uptake at 37° C showed in Figure 4-14 and the 
corresponding flow cytometry histograms (b). (c) Uptake mechanism study of 
EapCol-Lip-3 by Caco-2 cells in presence of endocytosis inhibitors, cytochalasin 
D (Cyto D), chlorpromazine (CPZ), Filipin III and MβCD in combination with 
lovastatin. Data are shown as mean ± SEM from three independent experiments 
(n= 3, N= 9). Statistical difference is considered significant with P-value < 0.05 (*), 


















































































4.6 Salmonella enterica growth curve and MIC determination 
Salmonella was cultured over time from a single colony of an overnight culture. 
The OD600 of each time point culture was measured and plated on agar plates to 
be counted colonies. The obtained data set expressing the bacterial growth, was 
plotted as time versus OD600 and bacterial count per mL (CFU/mL) as shown in 
Figure 4.17 a. Growth curve showed a typical bacterial growth characterized by 
an initial lag phase of 2 h, where bacteria go through an increase of their size and 
adapting to the environment. Afterwards, Salmonella started to divide indicated 
by the increase of the bacterial count over 2 h defined as exponential growth 
phase to reach approximately 2 x 1013 CFU/mL. Finally, the bacterial growth went 
to a stationary phase, in which cellular division was stopped due to a nutrient 
exhaustion and leading to cellular death. In order to ensure an optimal viability 
and pathogenicity of bacteria during anti-bacterial efficacy studies, bacterial 
cultures were all used during their exponential phase. From an overnight culture 
of Salmonella, an OD of 0.7 was inoculated further in fresh Nutrient Broth for 2.5 
h at 37° C before use. A morphological identification of Salmonella’s colonies was 
conducted using phase contrast microscopy from an overnight culture inoculated 
in fresh culture medium and plated to microscope slide. Salmonella colonies were 
characterized by a frizzy circular shape with a smoother appearance (Figure 4.17 
b). However, colonies of Salmonella plated on agar plates exhibited the same 
shape with raised surfaces (Figure 4.17 c). 






Figure 4.17. Salmonella characteristics 
(a) Growth curve expressed as optical density measured at 600 nm (OD600) and 
number of bacterial colonies (CFU/mL) versus time. (b, c) Images of Salmonella 
colonies in suspension plated on microscopic slide and colonies grown on agar 
plate respectively.  
The minimum inhibitory concentrations were determined after incubation of 
bacterial cultures of an OD of 0.1 with different treatments including colistin as 
free drug, Col-Lip-3 and EapCol-Lip-3 using different concentrations between the 
ranges of 0.125 µg/mL to 128 µg/mL. Fitting curves and IC50 as well as IC90 values 
are showed in Figure 4.18. Results indicated that colistin as free drug had an 
IC50 of 2.63 µg/mL and IC90 of 4.14 µg/mL after 18 h incubation period. While, 
50% of the bacterial growth was inhibited by 3.10 µg/mL and 3.35 µg/mL using 































5.53 µg/mL of EapCol-Lip-3 were required to reach 90% of bacterial growth 
inhibition. The values for liposomes formulations were higher than colistin drug 
which was expected as colistin encapsulated into liposomes would require more 
time to be released, however no significant difference was observed between 
non-functionalized liposomes and colistin-loaded liposomes functionalized with 
Eap Figure 4.18 d. 
 
Figure 4.18. Salmonella minimum inhibitory concentrations 
MIC fitting curves of Salmonella treated with colistin in red (Col, a), colistin-loaded 
liposomes in purple (Col-Lip-3, b) and Eap-functionalized liposomes, containing 
colistin in blue (EapCol-Lip-3, c) -treated Salmonella’s cultured samples over 18 
h at 37° C. (d) IC50 and IC90 values of Col, Col-Lip-3 and EapCol-Lip-3. Data are 
shown as mean ± SEM from three independent experiments (n= 3, N= 9). 




















































































4.7 Impact of Eap-functionalized liposomes on infected cells 
4.7.1 Infection parameters determination 
In order to evaluate the antibacterial efficacy of Eap-functionalized liposomes, 
loaded with colistin on intracellular Salmonella, establishment of an optimal 
infection settings are required for better interpretation of the efficacy as well as 
toxicity. HEp-2 cells and Caco-2 monolayer were infected with different MOI (10, 
25, 50 and 100) during 1 h incubation time at 37° C. Further treatment of the cells 
with gentamicin solution to eradicate extracellular Salmonella was conducted and 
cells were then, lysed to count bacterial colonies. Cells morphology was 
monitored during the study at each stage in order to ensure their viability and 
well-state after each treatment and treatment duration. Results showed that 
number of colonies reflecting intracellular Salmonella count (CFU/mL) in HEp-2 
cells, increased by increasing number of bacteria per cell in following x2 profile 
with each MOI reaching an maximum of approximately 3 million bacteria/ mL 
using an MOI of 100 (Figure 4.19a). 
 
Figure 4.19. Intracellular infection optimization 
(a) HEp-2 cells and (b) Caco-2 monolayer infected with MOI of 10, 25, 50 and 
100 for 1 h, and further treated with gentamicin solution (50 µg/mL) for 2 h. Cells 
were lysed and cell lysate was platted on agar plates. Bacterial colonies were 
































independent experiments (n= 3, N= 9). ). Statistical difference is considered 
significant with P-value < 0.0001 (****). 
On the other hand, number of bacteria which were able to invade Caco-2 
monolayer increased slightly by increasing MOI form 10 to 25, and no notable 
change was observed by using an MOI of 50. However, these values were higher 
than the values obtained with HEp-2 cells, especially with an MOI of 100, more 
than 4 million colonies/mL were capable to infect Caco-2 cells (Figure 4.19 b). 
Images of HEp-2 cells after each step were taken to ensure cell viability based 
on the morphology, no major observation were seen that could indicate cell death 
or damage except of small number of round-shaped cells which could be seen in 
all images (Figure 8.8). However, imaging of Caco-2 cells was not possible due 
to Transwells inserts setup. 
4.7.2 Antibacterial efficacy of EapCol-Lip-3 
HEp-2 cells and Caco-2 monolayer were treated with different liposomal 
formulations as well as colistin as free drug. A dose of 30 µg/mL colistin was used 
for the study and 20 µg/mL of Eap was used for functionalization. Colistin as free 
drug as well as Col-Lip-3 mixed separately with Eap immediately prior treating 
cells with liposomes were used as controls to evaluate binding affinity of Eap. 
Results showed that EapCol-Lip-3 were able to reduce significantly the infection 
load of Salmonella-infected HEp-2 cells by 36% compared to Col, Lip-3, Col-Lip-
3, as well as to Col and Col-Lip-3 mixed with Eap (Figure 4.20 a). Results using 
Caco-2 monolayer showed a similar tendency of a significant infection reduction; 
approximately 30%after application of EapCol-Lip-3 in comparison to samples 
and controls. However, as shown previously in uptake studies that non-
functionalized liposomes (Col-Lip-3) were able to be taken up by Caco-2 cells, 
which was confirmed in this experiment by a decrease of the infection load by 
11% after treating Caco-2 cells with Col-Lip-3 (Figure 4.20 b). On the other hand, 
Eap-mixed Col and Eap-Mixed Col-Lip-3, showed a reduction of less than 9% in 
both cell setups (Figure 4.20 a, b). 






Figure 4.20. Antibacterial efficacy 
Killing percentage of Col, Lip-3, Col-Lip-3, EapCol-Lip-3 and Col, Col-Lip-3 mixed 
with Eap of Salmonella-infected HEp-2 cells (a) and Salmonella-infected Caco-2 
monolayer (b). HEp-2 cells and Caco-2 cells were incubated with all samples and 
controls (non-treated, infected cells) for 2 h and 4 h respectively at 37° C and 5 
% CO2. Data are shown as mean ± SEM from three independent experiments (n= 
4, -N= 12). Statistical difference is considered significant with P-value < 0.05 (*), 
< 0.01 (**). 
4.7.3 Cell viability during infection studies 
A cell viability assessment was conducted in order to evaluate the state of 
infected cells after treatment with liposomes and after several incubation periods 
during the study. Both cell lines were subjected to a Live/Dead staining after the 
gentamicin killing of extracellular bacteria. Cells were stained with Live/Dead kit 
and measured using flow cytometry. Results showed that using liposomal 
formulations (Lip-3, Col-Lip-3 and EapCol-Lip-3) as well as colistin as free drug 
(Col) did not cause any cellular death, in which a similar percentage of live cells 
was obtained with all samples comparable to the control (+) (non-infected and 
non-treated cells) in both cell lines (Figure 4.21). Approximately 10% of dead 
cells was obtained which reflect the number of lost cells during multiple washing 
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control (-) were used to gate the flow cytometer parameters in two areas, live 
cells with optimal size and optimal granulation situated in the middle of plotted 
cell dots as forward Scattering (FSC) versus Side scattering (SSC), while dead 
cells were located on left vertical middle to upper area indicating lower size 
(debris).  
 
Figure 4.21. Cell viability after infection studies 
Viable cells percentage of HEp-2 calls (a) and Caco-2 monolayer (c) using 
Live/Dead after treatment of Salmonella-infected cells with liposomal 
formulations Lip-3, Col-Lip-3 and EapCol-Lip-3 as well as colistin as free drug 
(col). Corresponding flow cytometry histograms of HEp-2 cells (b) and Caco-2 




























































cells as control (+) as dead cells. Data are shown as mean ± SEM from three 
independent experiments (n= 4, -N= 12). 
4.7.4 Eap dose titration 
Liposomes containing 30 µg/mL of colistin were functionalized with different Eap 
concentrations, to evaluate the potency of Eap to induce liposomal internalization 
and therefore lead to the highest killing percentage. Results showed an increase 
of the killing percentage from 17% to approximately 50% by increasing the Eap 
concentration from 7 µg/mL to 20 µg/mL in HEp-2 cells. However, using 40 µg/mL 
of Eap did not show any significant increase of the antibacterial effect of 
liposomes (Figure 4.22 a). On the other hand, results of Caco-2 cells, showed a 
22 % decrease of infection load using Col-Lip-3 functionalized with 7 µg/mL of 
Eap, an increase of Eap concentration did not show any significant improvement 
of the bacterial killing (Figure 4.22 b). 
 
Figure 4.22. Eap-dose titration 
HEp-2 cells (a) and Caco-2 cells (b) were incubated with Col-Lip-3 functionalized 
with 7, 12, 20 and 40 µg/mL of Eap for 2 h and 4 h respectively at 37°C and 5% 
CO2. Data are shown as mean ± SEM from three independent experiments (N= 
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4.7.5 Colistin-dose response 
Salmonella-infected cells were treated with liposomes functionalized with 20 
µg/mL of Eap and titrated with different colistin concentrations ranged from 30 
µg/mL to 200 µg/mL. Results showed that the killing percentage increased from 
36% to almost 60% by increasing colistin dose on Salmonella-infected HEp-2 
cells (Figure 4.23 a). While, an increase from 20% to only 40% was observed 
after treatment of Caco-2-infected monolayer with EapCol-lip-3 containing colistin 
dose up to 200 µg/mL (Figure 4.23 b). 
 
Figure 4.23. Colistin-dose response 
Percentage of killing after treatment of HEp-2 cells (a) and Caco-2 cells (b) with 
EapCol-Lip-3 in different colistin doses 30, 50, 80,100, 150, 200 µg/mL. 
Liposomes were functionalized with 20 µg/mL of Eap and cells were incubated 
for 2 h (HEp-2 cells) and 4 h (Caco-2 monolayer) at 37° C and 5% CO2. Data are 
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4.8 In vivo pilot study 
In vivo experiment was conducted using mice infected with Salmonella 
Typhimurium, and treated with EapCol-Lip-3 as well as InvCol-Lip-3 to compare 
the two therapeutic strategies. Colistin as free drug was used beside PBS as 
controls. Results were divided in two parts, CFU in content of the small intestine 
and cecum to evaluate the impact of treatment on extracellular bacteria, and CFU 
in tissue of the aforementioned organs, to evaluate the intracellular killing 
efficiency (Figure 4.24 a - d). Body weight was monitored during the study 
(Figure 4.24 e). Results of both small intestine and cecum content showed that 
colistin (as free drug) had a significant antimicrobial effect in comparison to the 
untreated group (PBS) as well as to the liposomal-based formulations. This is 
expected as different time points for such read-out is required for liposomal 
formulations due to the slow release of colistin from the liposomal compartment. 
InvCol-Lip-3 showed a significant reduction of the infection in the cecum content 
but not in the small intestine compared to untreated group. In the tissue colistin 
again had the most potent effect on Salmonella’s infection compared to EapCol-
Lip-3 and InvCol-Lip-3, which was not expected as colistin cannot penetrate into 
the GI tract cellular membranes. Regarding the body weight, results showed 
approximately 4% decrease of animals’ body weight upon treatment with EapCol-
Lip-3 (Figure 4.24 e), while <3% was observed with InvCol-Lip-3 and no major 
changes with colistin and PBS. 






Figure 4.24. Liposomal treatment of Salmonella-mouse modal 
Bacterial counts (CFU/g) in cecum content (a), cecum tissue (b), small intestine 
content (c) and small intestine tissue (d) of mice treated with EapCol-Lip-3, 
InvCol-Lip-3, colistin and PBS after 18 h. (e) Body weight monitoring over the 
study duration. Data are shown as median ± SEM from five mice (P-value < 0.05 
(*), < 0.01 (**)). 
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5.1 Colistin-loaded liposomes for oral delivery 
Liposomes as lipid-based nanocarriers are commonly used in the pharmaceutical 
and cosmetic industries. Since their discovery in 1964, this particular field in 
nanotechnology has known successful progress and achievements. These 
include Doxil®, a formulation consisting of 80 - 90 nm PEGylated liposomes 
containing doxorubicin for treatment of Kaposi's sarcoma and recurrent ovarian 
cancer, and Abelcet®, a 250 nm sized liposomal formulation encapsulating 
amphotericin B to treat fungal infections (Working et al. 2008; Weissig et al. 
2014). These represent a breakthrough in nanomedicine evolution. However, 
most of the FDA-approved lipid-based formulations are designed for parenteral 
administration routes. Administration by the highly convenient oral route presents 
several challenges, particularly for liposomes, due to their inherent instability in 
the GI tract as well the presence of different biological barriers including mucus 
layer and the epithelial cellular barrier. Therefore, numerous efforts are being 
focused on achieving efficient liposomal drug delivery via the oral route. 
Utilization of long chain phospholipids together with cholesterol has proven to 
stabilize orally administered liposomes. Liposomes composed of DPPC and 
DSPC, phospholipids which exhibit high transition temperatures (Tm) of 41 °C and 
55 °C respectively, have shown an ability in previous studies to protect their 
payload in simulated gastric and intestinal media such as in low pH medium and 
in the presence of enzymes (Kokkona et al. 2000b; Rowland and Woodley 1980a; 
Mannock et al. 2006). Therefore in the current work, different liposomal 
formulations were prepared using DPPC and DSPC as main phospholipids in 
addition to 30% (w/w) cholesterol [Lip-1 (DPPC:CHOL), Lip-2 (DSPC:CHOL) and 
Lip-3 (DPPC:DSPC:CHOL)]. These liposomal formulations shared similar 
colloidal parameters: a mean diameter of 200 nm, a monodisperse size 
distribution and a negative surface charge (Figure 4.1). Colistin, a polypeptide 
anti-infective, was then selected to be loaded into these formulations, due to the 
recent attention it has attracted as a last resort anti-infective in light of the 
uncontrollable increase in bacterial resistance and lack of new antibiotic 





alternatives (Falagas and Kasiakou 2005; Li et al. 2006; Li et al. 2005). Colistin 
is effective against most Gram negative bacteria especially MDR strains such as 
Pseudomonas aeruginosa, however in practice it is mainly used as parenteral or 
inhalable forms (Gurjar 2015; Li et al. 2005). Therefore, there is considerable 
interest in the optimization of colistin use. Different concentrations of colistin were 
loaded into all three liposomal formulations, in order to determine the optimum 
loading conditions. A loading concentration of 4 mg/mL was chosen as this 
resulted in optimal entrapment efficiency and loading capacity in comparison to 
the other tested concentrations. Moreover, it showed less differences between 
the three formulations and therefore an optimal choice for comparison 
(Figure 4.5). Further optimization steps such as an increase of shaking speed 
during lipid film hydration and short sonication cycles before extrusion, led to an 
increase in EE (Table 4). The achieved EE is considered to be quite high as lipid 
film hydration method is mostly known for lower capacity of encapsulating 
hydrophilic molecules when compared to remote loading (Muppidi et al. 2012; 
Colletier et al. 2002). This EE could be due to the fact that colistin possesses a 
lipid tail which could interact with the liposomal bilayers. Such a high EE was also 
observed by Wallace and his colleagues who encapsulated CMS in DOPC : 
CHOL (2:1) liposomes (Wallace et al. 2012). Moreover, the obtained LC (~ 50%) 
in the current work, is also considered high as the loading of water soluble drugs 
into other nanocarriers, such as polymeric nanoparticles, is generally lower than 
10% (Barichello et al. 1999; Cai et al. 2015; Qin et al. 2017; Zheng et al. 2014).  
Thermal characterization of Col-Lip-1, Col-Lip-2 and Col-Lip-3 (corresponding to 
Lip-1, Lip-2 and Lip-3 formulations loaded with colistin) using DSC showed an 
abolishment of the phase transition temperature of liposome components – 
namely, DPPC (41 °C) and DSPC (55 °C) – in the range of 0 °C to 80 °C. This is 
likely due to the incorporation of 30% cholesterol into the liposomal bilayer, which 
would positively affect the stability of these liposomes and has been widely 
documented previously to abolish phase transition temperatures (Mannock et al. 
2006; Fritzsching et al. 2013).  
As mentioned before, the aim of the current work was to develop a liposomal 
formulation able to deliver colistin orally. This represents a significant challenge 





in terms of formulating such a system capable of withstanding the harsh GI tract 
conditions. To characterize liposome integrity under such conditions, stability 
studies in GI-biorelevant media simulating stomach and intestinal environments 
were performed. Incubation in FaSSGF and FaSSIF, characterized by a low pH 
(pH=1.6) and the presence of bile salts/phospholipids respectively, did not affect 
the colloidal parameters of any of the three liposomal formulations compared to 
the control. Moreover, no major effect on the integrity of these liposomes was 
observed, as only 10 to 15% of colistin was released from the formulations during 
the incubation time. However, no colistin release was observed in PBS as a 
control, indicating that presence of bile salts and the lower pH challenge the 
formulations. Incubation in FeSSIF, showed no major changes in the size of the 
three formulations with an increase of the PDI to 0.4. On the other hand, 
incubation of liposomes in FaSSIF containing enzymes (lipase) resulted in a huge 
size increase in all the formulations accompanied by an increase in PDI. This 
result was contrary to what was expected, as any liposome degradation was 
rather anticipated to result in a decrease in particle size (Figure 4.7). Therefore, 
in order to further investigate the effect of FaSSIF containing enzymes medium 
on colistin-loaded liposomes, cryo-TEM was utilized to visually examine 
liposomes after incubation with media. Surprisingly intact spherical-shaped 
liposomes were observed, but additional different colloidal structures were 
observed which were also present in the medium alone (Figure 8.5). The 
presence of such colloidal assemblies ranging from micelles to larger structures 
including vesicles and discs has been widely investigated and proven to be a very 
important factor in the solubility of hydrophobic drugs in the GI tract (Hjelm et al. 
1995; Nawroth et al. 2011; Müllertz et al. 2015; Riethorst et al. 2016; Elvang et 
al. 2016; Clulow et al. 2017). The presence of these colloidal assemblies could 
explain the increase in liposome size and PDI as measured by DLS. This 
suggests that colloidal characterization in conjunction with the use of complex 
media including FeSSIF should be conducted carefully with optimal techniques, 
and should also be accompanied by microscopic evaluation. No major changes 
in the size upon the incubation in FeSSIF with all formulation, while PDI values 
indicated a heterogeneous size distribution, as indicated above due to the 
presence of other colloidal structures such as micelles. Regarding the surface 





charge, an increase in zeta-potential values was observed in the FaSSGF  and 
FeSSIF due to high pH and high salts concentrations in the media respectively 
which plays a major role in the electrostatic interactions (Yan and Huang 2009). 
In terms of colistin retention, Col-Lip-1 released almost 60% in FeSSIF, and less 
than 20% from Col-Lip-2 and Col-Lip-3 (Figure 4.8). This difference in behavior 
in FeSSIF is due to the presence of DSPC in Col-Lip-2 and Col-Lip-3. The long 
chain fatty acids of DSPC compared to the shorter chains of DPPC were able to 
enhance the stability of both Col-Lip-2 and Col-Lip-3 liposomal formulations and 
prevent the high leakage of colistin. This finding align with previous study results 
in which saturated phospholipids with long carbon chains such as DSPC (Tm = 
55 °C) with cholesterol showed better stability in the presence of bile salts or 
enzymes compared to DMPC-containing liposomes (Kokkona et al. 2000a; 
Rowland and Woodley 1980b). In contrast to DSPC, liposomes composed of 
phospholipids with lower Tm such as dimyristoyl phosphatidylcholine (DMPC) are 
susceptible to a disruption of lipid bilayers in the presence of bile salts and to the 
effect of lipases, and are therefore unable to maintain intact structures (Kokkona 
et al. 2000a; Liu et al. 2015; Shukla et al. 2016). This affects more hydrophilic 
drugs and causes their leakage from liposomes, while poorly soluble drugs 
remain encapsulated in mixed micelles formed as a result of liposome 
degradation (Wu et al. 2015; Tian et al. 2016). Due to the observation that Col-
Lip-1 released more than 50% of its loaded colistin in FeSSIF in 5 h time period, 
further studies were carried out only with Col-Lip-2 and Col-Lip-3. 
5.2 Eap mediates the internalization of liposomes 
Oral delivery of liposomes is impeded by different barriers including the instability 
in the GI tract as discussed in Section 5.1, as well as to the difficulties to cross 
biological membranes (Wu et al. 2015; He et al. 2019). Therefore, different 
strategies have been developed to facilitate penetration across the enteric 
epithelium. One example is the incorporation of permeation enhancers into 
liposomes, which interferes with tight junctions or increases the liposomal fusion 
with cell membranes (Ganem-Quintanar et al. 1997; Parmentier et al. 2010; 
Maher et al. 2016). As another approach, coating of liposomal surfaces with 
permeation enhancing polymers has been also widely investigated and reported 





to be efficient to some extent – this includes polymers such as chitosan, which 
has the ability to interfere with tight junction proteins and initiate paracellular 
transport (Thanou et al. 2001; Zambito et al. 2006; Kowapradit et al. 2012; Chen 
et al. 2012). Furthermore, to achieve more specific targeting by mimicking the 
way nutrients are absorbed, or the process by which pathogens are internalized 
into epithelial cells of the GI tract, liposomal surfaces have been functionalized 
with nutritional ligands (Wang et al. 2014; Zhang, X. et al. 2014; Anderson et al. 
2001; Anderson et al. 1999) or invasive moities (Werle et al. 2010; i, K. et al. 
2011; Labouta et al. 2015; Menina et al. 2016). InvA497, a well characterized 
bacterial-derived protein, interacts with α5β1 integrin receptors and promotes the 
internalization of Yersinia spp. into mammalian cells (Dersch and Isberg 1999, 
2000; Bühler et al. 2006; Uliczka et al. 2011).This protein has been coupled to 
several nanocarriers such as latex nanoparticles (Hussain and Florence 1998), 
polylactide-co-glycolide (PLGA) nanoparticles (G. F. Dawson and G. W. Halbert 
2000), microparticles (S. E. Autenrieth and I. B. Autenrieth 2008) and liposomes 
(Menina et al. 2016; Labouta et al. 2015), to enhance their uptake by eukaryotic 
cells. The promising results of these studies have opened a way to the use of 
bacteria-derived proteins as invasive moieties and the mimicking of pathogen 
invasion by adopting some of their strategies. S. aureus, classified as an 
extracellular bacteria, has been shown to possess the ability to invade eukaryotic 
cells using different types of proteins (Lowy 2000; Josse et al. 2017). Eap, a 
virulence factor secreted by S. aureus, which can re-bind again to the bacteria 
itself, mediates its binding and internalization. It is also not well understood to 
date how Eap mediates the binding and the invasion of S. aureus into eukaryotic 
cells. Josse and his colleagues gathered all published research investigating 
S.aureus internalization mechanisms in a recent review, in which two suggestions 
of Eap mechanism as known to-date were stated: (I) Eap interacts with α5β1 
integrin receptors after binding to fibronectin (Fn), or (II) Eap triggers actin-
dependent phagocytosis (Josse et al. 2017). Therefore, the novelty of this work 
is based on functionalization of liposomes containing colistin with Eap, to further 
demonstrate the ability of this protein to promote invasion and also to investigate 
its mechanism of internalization. Coupling of ligands on liposomes is mostly 
performed via a covalent linking using either common coupling reagents such as 





carbodiimides (EDC) (Sheehan and Hlavka 1956), triazines (DMTMM) (Kamiński 
et al. 2005) or more sophisticated methods (Dunetz et al. 2016). Besides, the 
covalent coupling which offers more control of the ligands orientation and also 
the amount, Eap in this case was functionalized via a physical adsorption on the 
liposomal surface due to its adhesive properties. The high percentage of FE 
obtained using surface adsorption confirms clearly that Eap possess a strong 
adhesion properties which allow Eap to stick to liposomal surface (Figure 4.9). 
These adhesion properties have been investigated previously by Haggar et al. 
showing that Eap mutant S. aureus (Newman mAH12) were found to have a 
reduced ability to internalize into fibroblasts as well as epithelial cells when 
compared to wild-type Eap gene. They also showed in their study that by adding 
Eap to the mutant strain, internalization role of Eap was restored and resulted in 
an increase of the uptake of these pathogens by the tested cells (Haggar et al. 
2003). This high adhesion properties of Eap have affected negatively liposomes 
in a ways that after functionalization, liposomes tend to form aggregates. This 
observation is in agreement with previous findings that Eap has the ability to 
spontaneously aggregate S. aureus in concentration-dependent manner (Palma 
et al. 1999; Hussain et al. 2008; Thompson et al. 2010). However, sonication of 
Eap-functionalized liposomes lead to restoration of liposomal size and no major 
changes were observed during consecutive 4 days (Figure 4.10, Figure 4.11). 
The sonication protocol was applied for short time as recommended by Zhu et.al 
to ensure that the structure as well as the functionality of Eap would not be 
compromised (Zhu et al. 2018). 
In the current work, the ability of Eap to promote the binding and internalization 
of liposomes was first evaluated by performing uptake studies. Subsequent to 
cytotoxicity assessment, which showed no adverse effects of colistin, Eap or 
liposomal components at defined dose range (Figure 4.13), uptake of liposome 
formulations in epithelial cells of the HEp-2 cell line and in Caco-2 monolayers as 
a GI epithelial cell model was assessed. The uptake studies were carried out only 
with Col-Lip-3 as functionalization study showed that only this formulation 
functionalized via surface adsorption exhibited the highest functionalization 
efficiency. The outcomes of the uptake study showed, for the first time, that 





functionalization of liposomes with Eap promoted significantly the uptake of 
colistin-loaded liposomes (EapCol-Lip-3) in HEp-2 cells compared to non-
functionalized liposomes. Uptake results of non-functionalized liposomes (Col-
Lip-3) in HEp-2 cells showed no-to-low uptake efficiency after 1 h and 2 h. While, 
using 5 µg/mL of Eap to functionalize these liposomes induced approximately 50 
% of uptake after 2 h, and by increasing the Eap concentrations to either 10 
µg/mL or 20 µg/mL, the uptake efficiency increased to > 95%. On the other hand, 
similar uptake efficiency was observed with Col-Lip-3 and EapCol-Lip-3 
functionalized with 5 µg/mL in Caco-2 monolayer (<10% and ~40% after 2 h and 
4 h respectively). Whereas, increasing Eap concentration lead to increased 
uptake efficiency in a concentration-dependent manner (Figure 4.14). 
Functionalizing liposomes with 20 µg/ml Eap was sufficient to promote almost 
100% uptake of liposomes into both cell types. This concentration is comparable 
to that used in a study by Bur and his colleagues, where it was shown that pre-
incubation of HaCaT cells with 10 µg/mL of Eap was sufficient to mediate the 
cellular uptake of S. aureus (Eap-mutant starin SA113), whereas 40 µg/mL 
induced a saturation of its internalization. Moreover, pre-incubation of HaCaT 
cells with Eap promoted the uptake of S. epidermidis and S. lugdunensis as well 
as Escherichia coli (Bur et al. 2013). The method of Col-Lip-3 functionalization 
with Eap either covalently or via surface adsorption did not affect the efficiency of 
the uptake (Figure 8.6). This suggests that Eap does not require a specific 
orientation or specific functional group to promote the binding as well as the 
internalization. This is in direct contrast to InvA497 – we have previously shown 
that coupling InvA497 to DPPC-based liposomes requires a covalent coupling, in 
which the free C terminal group plays an important role in mediating the uptake 
of these liposomes (Labouta et al. 2015). Moreover, an InvA497 derivative 
(InvA197) was not able to promote the internalization of latex beads efficiently 
compared to InvA497 (Dersch and Isberg 1999).  
The ability of Eap to promote liposomal binding and/or internalization into HEp-2 
cells was further compared to InvA497-functionalized Col-Lip-3 after 1 h 
incubation time. Results indicated that Eap was more efficient in achieving >75% 
Rhod-positive cells with all tested concentrations compared to InvA497, where 





only 40% of Rhod-positive cells was achieved with the highest used concentration 
(Figure 8.7). However, it is difficult to make an appropriate comparison as the 
two proteins differ in their mechanism of action, several aspects need to be 
considered such as concentration, coupling method and incubation time, e. g. 
InvA497 requires higher concentration to be used to functionalize liposomes (15 
times Eap concentration to achieve 95% positive signal in 1 h, Figure 8.7). 
The exact mechanism by which Eap mediates binding and uptake is not yet well 
understood, and therefore further investigations into this aspect would be 
valuable. To understand how Eap enhances the uptake of liposomes by HEp-2 
cells and Caco-2 cells, one should look first at the non-functionalized liposomes. 
As mentioned before, in contrast to HEp-2 cells, 35% of Caco-2 cells were able 
to take up non-functionalized liposomes after 4 h indicating differences in their 
uptake mechanism (Figure 4.14). Despite the enormous amount of research on 
liposomes that has been conducted, the uptake mechanism of liposomes has not 
been clarified completely (Düzgüneş and Nir 1999). Most of the reports on 
liposomal internalization showed that these nanocarriers are taken up via 
clathrin-dependent endocytosis (Ziello et al. 2010; Rejman et al. 2005; Andar et 
al. 2014), whereas other studies demonstrated that caveolae-mediated pathway 
plays an essential role in the uptake of liposomes (Andar et al. 2014; 
Kheirolomoom and Ferrara 2007; Fiandaca et al. 2011; Alshehri et al. 2018). On 
the other hand, it has been shown also in early studies that internalization of 
liposomes could be achieved passively. Papahadjopoulos et al. found that 
liposomes can fuse with cell membranes and release therefore their payload into 
the cell (Papahadjopoulos et al. 1973). However, the internalization of liposomes 
or nanocarriers in general is influenced by several factors, such as size, surface 
charge, shape, composition, and surface chemistry (Rejman et al. 2004; Gratton 
et al. 2008; Nangia and Sureshkumar 2012; Ernsting et al. 2013). Functionalizing 
liposomes with Eap resulted in almost 100% uptake. However, lowering the 
incubation temperature from 37 °C to 4 °C inhibited the uptake only in Caco-2 
cells but not in HEp-2 cells, indicating that the uptake in Caco-2 cells is energy-
dependent, while in HEp-2 cells passive uptake is likely to be occurring 
(Figure 4.16 a, b).  





Several pathways are involved in energy-mediated uptake (pinocytosis), however 
the study of these various pathways is still an evolving domain (Kuhn et al. 2014). 
One of the well-investigated mechanisms is clathrin-dependent endocytosis, via 
which it has been shown that nanocarriers with a size <200 nm may be taken up. 
The binding arrangement of clathrin- coated pits to envelop the cargo leads to 
the formation of clathrin-coated vesicles and further to cargo internalization (Chen 
et al. 2018). Transferrin is considered as a marker for this pathway as it binds to 
the transferrin receptor and initiates uptake via clathrin-mediated endocytosis 
(Ivanov 2008). Caveolin-dependent endocytosis on the other hand, is 
characterized by small flask-shaped invaginations of the cell membrane with an 
enrichment of caveolin-1 (Nabi and Le 2003) This pathway is involved in 
particular for the uptake of some pathogens such as SV40 virus and cholera toxin 
and in which this latter is usually selected as marker for caveolin-mediated 
endocytosis (Ivanov 2008). Macropinocytosis, by contrast, is considered an 
unspecific endocytosis pathway, characterized by the engulfment of liquid 
macromolecules, in which the macropinosomes have a size of up to 5 µm (Jones 
2007). There is also a class of clathrin- and caveolin-independent endocytosis, in 
which various sub-pathways are involved such as dynamin-mediated 
endocytosis, lipid rafting and the flotillin-dependent pathway (Mayor and Pagano 
2007). Over the years, several studies have utilized various pharmacological 
inhibitors to identify a specific pathway for uptake of different molecules, 
pathogens and also nanocarriers. However, there are a number of studies which 
have highlighted the lack of specificity of these inhibitors (Vercauteren et al. 2010; 
dos Santos et al. 2011). Chlorpromazine as a cationic amphiphilic drug is known 
to interfere in the binding of clathrin and its proteins leading to inhibition of 
clathrin-coated pits formation and thereby, inhibition of clathrin-mediated 
endocytosis in a reversible manner (Chen et al. 2018). Methyl β-cyclodextrin, is 
a cyclic oligomer of glucopyranoside which extracts steroids from the cell 
membrane in a reversible manner leading to cholesterol inhibition and therefore, 
is utilized as a clathrin and caveolin-independent pathway inhibitors (Vercauteren 
et al. 2010). Macropinocytosis is known as an actin-driven pathway that forms 
protrusions, engulfing large fragments in a suspended environment. Through the 
de-polymerization of actin filaments, cytochalasin D is utilized to inhibit 





macropinocytosis (Kanlaya et al. 2013). Filipin III is an antibiotic which binds to 
the cholesterol present in cell membranes and induces formation of aggregates 
that interfere with the caveolin-dependent uptake mechanism (Schnitzer et al. 
1994). While a large number of inhibitors are therefore available, it is important 
to state that toxicity of these inhibitors play a major role in their function, and 
requires an optimization of the used concentrations which varies between 
different cell types (Dutta and Donaldson 2012). 
To dissect the type of energy-mediated pathway involved in liposomal 
internalization in Caco-2 cells, cells were incubated with EapCol-Lip-3 in the 
presence of endocytosis inhibitors. Results showed that all inhibitors had 
(varying) inhibitory potential on the uptake of liposomes (Figure 4.16). This 
strongly suggests that Eap-induced liposomal uptake depends on several 
pathways, but that this mainly occurs via caveolae-mediated endocytosis. Those 
results represent a starting point in elucidating the Eap-mediated mechanism of 
internalization, however further studies using several cell types are required to 
draw a complete picture of how it works. 
5.3 Impact of Eap-functionalized liposomes containing 
colistin on intracellular infection 
Targeting intracellular bacteria using liposomes or other nanocarriers such as 
polymeric or solid lipid nanoparticles has been widely investigated. However, 
their efficacy has mainly been studied in phagocytic cells such as macrophages, 
in which the delivery of the nanoparticle system and/or the payload is not limited 
due to the ability of these cells to engulf foreign particulates (Salouti and Ahangari 
2014). In contrast, , achieving an intracellular killing effect within non-phagocytic 
cells requires more effort such as functionalization of nanocarrier systems with 
invasive moieties (Goes and Fuhrmann 2018). As mentioned above, the current 
work showed that Eap is able to mediate liposome internalization in HEp-2 cells 
and Caco-2 monolayers; however their ability to release colistin intracellularly 
remained to be seen. Therefore, the efficacy of Eap-functionalized liposomes 
containing colistin (EapCol-Lip-3) to deliver colistin intracellularly was evaluated 
by their ability to kill intracellularly-located pathogens. For this purpose, HEp-2 





cells and Caco-2 cells were infected with enteroinvasive Salmonella enterica. 
After killing extracellular bacteria using gentamicin, cells were treated with 
different liposomal formulations as well as free colistin as a control. EapCol-Lip-
3 was able to reduce the infection load in HEp-2 cells and Caco-2 cells by 32% 
and 30% respectively. Interestingly, Col-Lip-3 without Eap functionalization 
reduced the infection load by 11% in Caco-2 cells, but had no effect on the 
infection load in HEp-2 cells (Figure 4.20). This aligns with the above results of 
uptake studies which showed that Caco-2 cells had a basal liposome uptake 
ability in the absence of Eap (Figure 4.14). In addition, the anti-infective efficacy 
of Eap-functionalized liposomes was Eap and colistin dose-dependent, with 
uptake into HEp-2 cells reaching almost 60% following a 2 h incubation with 
liposomes containing 40 µg/ml Eap / 30 µg/ml colistin or 200 µg/ml colistin / 20 
µg/ml Eap (Figure 4.22, Figure 4.23). In a previous study, we could show a 
similar intracellular killing effect on Y. pseudotuberculosis and S. enterica using 
a different bio-inspired delivery system, which was based on targeting α5β1 
integrin receptors of the GI tract (Labouta et al. 2015; Menina et al. 2016). 
However invasin-based nanoparticles are able only to target specific cell types 
expressing α5β1 integrin receptors in the GI tract. Eap on the other hand is able 
to interact with a wider variety of cell types and thereby offers a broader coverage 
to eradicate intracellular pathogens. 
In vivo testing of such a system requires an established model. The conducted 
pilot study tried to establish Salmonella- infection mouse model to test liposomes. 
This model was not conclusive in a way that colistin was able to kill intracellular 
bacteria (in tissue). The fact that colistin lack the ability to penetrate through 
biological membranes raised a critical question: whether these results indeed 
indicate the anti-bacterial effect on intracellularly-located Salmonella or also 
includes extracellularly and/or bounded- bacterial counts. Due to the complexity 
of such model, various factors should be taken in consideration while designing 
the study in the future, such as the administrated dose, the treatment duration 
and more important optimal read-outs and/or tests to address each aspect of 
such an investigation. 





However, the use of this bacteria-derived protein as an invasive moiety to 
facilitate the intracellular delivery of nanocarriers would require deeper 
investigations, in order to fully understand the function and optimize the system 
towards different targets and/or different administration routes. Moreover, in vivo 
studies and/or complex cell models could be considered as further steps to be 
performed, as in vitro studies show only the proof of concept, which needs to be 
investigated further in more sophisticated systems. 
  





A lipid-based nanoparticulate system encapsulating colistin, a hydrophilic 
polypeptide antibiotic, was first formulated to deliver colistin orally. Withstanding 
the GI tract environment including acidic medium and enzymatic degradation was 
achieved by the assembly of liposomes containing long chain phospholipids 
together with cholesterol, which led to improving the liposomal stability. In order 
to facilitate the intracellular delivery of colistin, which is poorly permeable through 
cellular membranes, a subsequent functionalization of the liposomal surface with 
the bacteria-derived protein, Eap, was performed. The presence of Eap on 
liposomal surfaces enabled the internalization of these liposomes into epithelial 
cells, resulting in a substantial killing of intracellular S. enterica. As the 
internalization pathway mediated by Eap has not been well understood to date, 
the study provided valuable insight into the fact that depending on cell type, Eap-
mediated liposome internalization occurred in either an energy-dependent 
manner involving several pathways or in an energy-independent manner. Further 
investigations are required to characterize in detail the mechanisms by which Eap 
binds to and penetrates into cells. The importance of this work is to show that 
bacterial-derived invasion factors are a strategy to achieve higher accumulation 
of poorly-permeable drugs in non-phagocytic cells. For Eap, this was to our 
knowledge the first time to demonstrate enhanced uptake of a functional drug 
carrier. The principle of such bio-inspired invasion factors would be transferable 
to other topical application routes (e.g. urinary tract infections) and poorly 
accumulating anti-infectives. However, it would be important to investigate as 
such an invasion molecule; which directly derived from a rather abundant 
bacterium like S. aureus, can be used without modifications, or is would be a 
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8 Supplementary Figures 
 
 
Figure 8.1. Colistin analytic analysis 
Chromatograms of colistin A and B obtained by HPLC analysis, using gradient 
mode composed of 20:80 (v/v) acetonitrile: 0.1% TFA running for 10 min to reach 
50:50 (v/v). A flow rate of 1 mL/min was used and peaks were detected using a 
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Figure 8.2. Thermal Characterization 
Thermal analysis of Col-Lip-1, Col-Lip-2 and Col-Lip-3 using a heating rage from 
0 °C to 80 °C with a heating rate of 10 °C/min and the enthalpy changes (ΔHm) 
were plotted versus temperature. 
  



















Figure 8.3. 3D fluorescence imaging 
Representative confocal 3D uptake images of EapCol-Lip-3 by HEp-2 cells (a) 
and Caco-2 monolayer (b). Cells were treated with liposomes (labeled with 
rhodamine, red), stained for cell membrane (green), nucleus (blue), and fixed. Z-
Stack sections (20 sections) were taken for an area of 200 µm x 200 µm x 12 µm 

























Figure 8.4. Ortho-CLSM images of Eap-Col-Lip-3 uptake 
Representative Ortho view of Z -stack image of EapCol-Lip-3 uptake in HEp-2 
cells (a) and Caco-2 monolayer (b). Images were taken using 40x oil immersion 
objective and cell membrane was stained in green (Fluorescein), nucleus in blue 











Figure 8.5. Liposomal morphology after stability studies in FaSSIF-Enz 
Representative pictures of Cryo-TEM imaging showing simulated medium 
content and/or liposomes morphology (1, 2 and 3) Col-Lip-1, (4, 5) Col-Lip-2 and 
(6) Col-Lip-3. Images were taken directly after 5 h incubation in fasted state 
simulated intestinal fluid containing enzymes (FaSSIF-Enz) at 37° C. (7, 8 and 9) 
images of FaSSIF-Enz alone without liposomal formulation, indicating the 











Figure 8.6. EapCol-Lip-3 uptake comparison 
EapCol-Lip-3 functionalized with Eap either covalently using DMTMM (Cov) or 
adsorbed on liposomal surface via direct incubation with Eap (Ads). HEp-2 cells 
and Caco-2 monolayer were incubated with the samples for 2 h and 4 h 
respectively at 37° C. Results showed no significant difference between the two 
































Figure 8.7. Eap- and InvA197-functionalized col-Lip-3 comparison 
Col-Lip-3 was functionalized with InvA197 (InvCol-Lip-3) and with Eap (EapCol-
Lip-3). Liposomes were applied to HEp-2 cells for 1 h using different 
concentrations 5, 10 and 20 µg/mL of each protein. Samples were prepared by 
functionalizing liposomes with each concentration separately and no washing 
step (to remove non-bounded protein) was performed in order to keep the same 
liposomal concentration in each applied sample. Results indicates the efficiency 
of Eap to mediate liposomal binding and/or internalization in comparison to 
































Figure 8.8. Cell imaging during infection 
HEp-2 cells images during the infection study showing healthy elongated cells 
before infection (a), after addition of Salmonella (b) and after gentamicin 
treatment (c). Cells shared a similar morphology with presence of low number of 
round-shaped cells at all stages.  
a b c
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